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ABSTRACT 
Peptide transporter 1 (PepT1), a member of the proton-coupled oligopeptide 
transporter family, is known to transport di-/tri-peptides and peptidomimetic 
therapeutic agents across biological membranes. Due to its abundant expression in 
small intestine, broad substrate specificity and high transport capacity, PepT1 is 
considered an ideal oral drug delivery target and plays a pivotal role in transporting 
numerous pharmacological compounds. The therapeutic agent 5-aminolevulinic acid 
(5-ALA) is widely applied in photodynamic therapy and fluorescence diagnosis for 
the treatment of various cancers and non-malignant diseases. PepT1 knockout mice, 
available in our laboratory, provide a novel tool to investigate the role and 
quantitative significance of PepT1 in the intestinal absorption and pharmacokinetics 
of 5-ALA. In this project, experimental results from in situ perfusion and in vivo 
pharmacokinetic studies offer a deeper understanding of the PepT1-mediated 
intestinal absorption of 5-ALA. 
The effective permeability of 5-ALA was evaluated as a function of drug 
concentration, potential inhibitors and regional segments of the intestines using in situ 
perfusions in wildtype and PepT1 knockout mice. The results from in situ perfusions 
indicated that PepT1 accounted for approximately 90% of 5-ALA permeability in 
mouse small intestine. In wildtype mice, 5-ALA intestinal uptake was shown to be 
concentration dependent with an apparent Km of 13.4 mM, based on bulk 
xv 
 
concentrations of substrate. The differential segmental permeability of 5-ALA was 
consistent with PepT1 expression along the intestinal segments, in which high 
permeabilities of 1-2 x 10
-4
 cm/s were observed in the duodenum, jejunum and ileum 
of wildtype mice with little permeability in colon. In contrast, the residual 
permeability of 5-ALA in the duodenum, jejunum, and ileum of PepT1 knockout 
mice was only about 10% of that in wildtype mice and similar to that of colon 
permeability. The contribution of other transporters, including the amino acid 
transporter PAT1, in mediating the intestinal permeability of 5-ALA was minor at 
best. After oral administration (0.2 and 2 mol/g) of 5-ALA, the maximum plasma 
concentration (Cmax) and area under the plasma concentration-time curve (AUC) of 5-
ALA were decreased approximately 2-fold in PepT1 knockout mice as compared to 
wildtype mice. The tissue distribution results after 0.2 mol/g 5-ALA oral dose and 
intravenous pharmacokinetic study (0.01 mol/g) revealed that PepT1 had marginal, 
if any, effect on the in vivo disposition of 5-ALA. In conclusion, research in this 
dissertation project offered solid evidence in defining the significant role of PepT1 on 
the intestinal absorption and systemic exposure of 5-ALA after oral dosing.  
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CHAPTER 1                                                                                        
RESEARCH OBJECTIVE 
Proton-coupled oligopeptide transporter 1 (PepT1), a transmembrane 
protein with predominant expression at the intestinal epithelium, is responsible for 
the uptake of dipeptides and tripeptides, and break down products from dietary 
protein ingestion across the apical membrane into enterocytes. Due to its broad 
substrate specificity, high transport capacity and abundant expression in the small 
intestine, PepT1 is considered to play a pivotal role in the oral absorption of 
numerous peptidomimetic compounds. Besides di/tripeptides, PepT1 can 
transport a variety of therapeutic agents with different structural and chemical 
characteristics, including β-lactam antibiotics (e.g., cefadroxil), angiotensin 
converting enzyme inhibitors (e.g., enalapril) and antiviral prodrugs (e.g., 
valacyclovir). Recently, prodrug strategies that combine rational drug design and 
PepT1 targeted drug delivery have been employed to improve the intestinal 
bioavailability of poorly absorbed drugs after oral administration. 
5-Aminolevulinic acid (5-ALA), a photosensitizer agent, is widely applied 
in photodynamic therapy and fluorescence diagnosis for the treatment of various 
cancers and non-malignant diseases. Although 5-ALA is a non-peptide mimetic 
small molecule, previous research has indicated that PepT1 may play an important 
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role in facilitating 5-ALA intestinal absorption and its good oral bioavailability 
based on in vitro results. However, the transport mechanism of 5-ALA from the 
gastrointestinal tract lumen into the systemic circulation system is still poorly 
understood. Moreover, the relative contribution of intestinal transporter PepT1 in 
this process is unclear, as compared to other potential intestinal transporters such 
as the amino acid transporter PAT1.  
Genetically modified mice, with targeted disruption of the PEPT1 gene, 
have been established and characterized recently in our laboratory. Compared to 
in vitro experimental systems with exogenously expressed transporters, the 
availability of PepT1 knockout mice provides a powerful animal model to 
thoroughly examine the functional role of PepT1 in the transport of nutritional 
and pharmacological substrates (e.g., glycylsarcosine, cefadroxil, valacyclovir, 
fMet-Leu-Phe) under physiological conditions.  
The research objective of this project is to unravel the transport 
mechanism of 5-ALA intestinal absorption and characterize the quantitative 
contribution of PepT1 to the oral absorption and systemic exposure of 5-ALA 
after oral dosing. The two specific aims of this project are presented below as:  
(1) To characterize the role and relative contribution of PepT1 in the 
intestinal absorption of 5-ALA in wildtype and PepT1 knockout mice via 
in situ single-pass perfusion studies. 
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(2) To determine the impact of PepT1 on the in vivo intestinal 
absorption of 5-ALA and pharmacokinetic profiles after oral dosing in 
wildtype and PepT1 knockout mice. 
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CHAPTER 2                                                                                 
BACKGROUND AND LITERATURE REVIEW 
PROTON-COUPLED OLIGOPEPTIDE TRANSPORTERS 
Proton-coupled Oligopeptide Transporters (POTs) are a family of 
transporter proteins that translocate various di-/tri-peptides and peptidomimetics 
across the biological membrane (Herrera-Ruiz and Knipp 2003; Daniel and Kottra 
2004; Smith, Clemencon et al. 2013). According to the HUGO Gene 
Nomenclature Committee (HGNC) system, this transporter family is also known 
as solute carrier family 15 (SLC15). 
To date four members in POT family have been identified in mammals, 
denoted as PEPT1 (SLC15A1), PEPT2 (SLC15A2), PHT1 (SLC15A4), and 
PHT2 (SLC15A3). In virtue of expression cloning techniques applied in the 1990s, 
encoding genes of these four transporters were identified in succession. PEPT1 
was the first member cloned from a rabbit intestinal cDNA library (Fei, Kanai et 
al. 1994) and soon followed by PEPT2 which was cloned from a human renal 
cDNA library (Liu, Liang et al. 1995). The other two oligopeptide transporters, 
PHT1 and PHT2, were then isolated from a rat brain cDNA library (Yamashita, 
Shimada et al. 1997; Sakata, Yamashita et al. 2001). Dissimilar to their paralogs 
PEPT1 and PEPT2, the latter two transporters were demonstrated to recognize the 
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amino acid L-histidine as their substrate in addition to di- and tri-peptides. Few 
studies have been focused on the peptide/histidine transporters PHT1 and PHT2 
after their identification, therefore, little is known about their pharmaceutical and 
pharmacological relevance (Brandsch, Knutter et al. 2008). 
POT proteins vary in size from 572-729 amino acids across species (Table 
2.1) and they share sequence and structural similarities. PEPT1 and PEPT2 share 
high homology in amino acids sequence between species (i.e., 80-90% amino acid 
identity between human, rat, mouse, and rabbit). However, sequence similarity 
between different POT transporters within a given species is relatively low. The 
human PEPT1 protein consists of 708 amino acid residues and shares overall a 50% 
sequence identity and 70% similarity with hPEPT2, whereas PHT1 and PHT2 
proteins share much less sequence identity to PEPT1 and PEPT2 (i.e., 
approximately 20 % ~ 25%) (Botka, Wittig et al. 2000).  
It has been shown that POT transporters are proton driven symporters, 
using an inwardly direct proton electrochemical gradient and the negative 
membrane potential to drive the uptake of peptides across the cell membrane 
(Adibi 1997; Nussberger, Steel et al. 1997; Nussberger, Steel et al. 1997). Such a 
proton gradient is generally provided and maintained by exchange of proton and 
sodium in opposite direction. This feature of POT transporters differs from many 
other known membrane transporters that are dependent on ATP hydrolysis or Na
+
 
concentration gradient. 
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The unique tissue distribution and expression patterns for the different 
POTs have been elucidated. First, PEPT1 mRNA and protein were found to 
express in a variety of tissues with primary expression in the small intestine 
(Liang, Fei et al. 1995; Lu and Klaassen 2006; Jappar, Wu et al. 2010). 
Specifically, PEPT1 protein is localized at the brush-border membrane of 
intestinal epithelial cells (Ogihara, Saito et al. 1996; Thwaites, Ford et al. 1999). 
Lower expression of PEPT1 was detected in other tissues such as kidney, bile 
duct, liver, placenta, monocyte, and pancreas (Daniel and Kottra 2004; Smith, 
Clemencon et al. 2013). PEPT2 has a quite different tissue distribution pattern, 
compared to PEPT1, with a predominant expression in kidney and brain. 
Moreover, relative low expression of PEPT2 was also shown in lung, liver, heart, 
mammary gland, eyes, spleen, testis, prostate, ovary, and uterus (Lu and Klaassen 
2006; Kamal, Keep et al. 2008). Regarding to PHT1 and PHT2, much less 
information is available about the expression and tissue distribution. PHT1 
transcripts were found in the brain and eye (Yamashita, Shimada et al. 1997) and 
PHT2 transcripts were expressed primarily in the lung, thymus and spleen (Sakata, 
Yamashita et al. 2001). Recently, significant expression of PhT1 protein was 
detected in adult rodents (Hu, Xie et al. 2014). 
Due to their broad substrate specificity and differential tissue distribution, 
PEPT1 and PEPT2 have been extensively studied for their significant 
physiological and pharmacological roles in the absorption and disposition of 
peptide nutrients as well as peptidomimetic drugs (Daniel and Kottra 2004; 
Brandsch, Knutter et al. 2008; Rubio-Aliaga and Daniel 2008; Smith, Clemencon 
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et al. 2013). PEPT1 (low affinity and high capacity) as well as PEPT2 (high 
affinity and low capacity) were believed to recognize and transport a number of 
peptide-like therapeutic agents with different conformation, size, polarity, and 
charges. These peptide-like drugs include, but not limit to, some β-lactam 
antibiotics (e.g., cefadroxil), antitumor drugs (e.g., bestatin), angiotensin 
converting enzyme inhibitors (e.g., enalapril) and antiviral prodrugs (e.g., 
valacyclovir). Overall, PEPT1 is pharmaceutically relevant and considered as a 
promising target for rational drug design or prodrug strategy in the hope of 
enhancing the oral bioavailability of certain drugs. In my thesis project, PEPT1 is 
the topic of research interest, thus more detailed discussion with respect to PEPT1 
will be present in the next section.  
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PROTON-COUPLED OLIGOPEPTIDE TRANSPORTER 1 (PEPT1) 
Introduction  
Nutritional needs for nitrogen and amino acids in mammalian animals are 
met by absorption of free amino acids (~ 20%) and small peptides (~ 80%) 
derived from dietary proteins in the digestive tract (Matthews 1975; Webb, 
Matthews et al. 1992; Ganapathy, Gupta et al. 2006). Carrier-mediated transport 
systems have been identified to play a pivotal role in this process that deliver di- 
and tri-peptides from the intestinal lumen into the enterocytes (Figure 2.1). 
Specifically, this process was generally believed to be attributable to the activity 
of proton-coupled oligopeptide transporter 1 (PEPT1). 
The proton-coupled oligopeptide transporter 1 (PEPT1), the most widely 
studied member of the POT superfamily, was first isolated from a rabbit intestinal 
cDNA library in 1994 (Fei, Kanai et al. 1994). The successful cloning of rPEPT1 
was achieved by mRNA isolation from rabbit small intestinal mucosa, functional 
expression of the carrier protein in Xenopus laevis oocytes and followed by its 
transport activity assessment. To date, PEPT1 has been cloned across different 
species such as human, mouse, rat, sheep, chicken, pig and monkey (Liang, Fei et 
al. 1995; Saito, Okuda et al. 1995; Fei, Sugawara et al. 2000; Pan, Wong et al. 
2001; Chen, Pan et al. 2002; Zhang, Emerick et al. 2004; Klang, Burnworth et al. 
2005). Indeed, PEPT1 gene is conserved and highly homologous across species, 
since human PEPT1 shares at least more than 80% amino acid sequence identity 
with any other mammalian species listed above. Whereas, hPEPT2, the paralog of 
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hPEPT1, shares about 50% identity and 70% similarity with hPEPT1 in terms of 
amino acid sequence.  
Mammalian PEPT1 consists of 707-710 amino acid residues depending on 
species. Human PEPT1 is composed of 708 amino acid residues with a molecular 
weight of 78 kDa, and the gene is mapped on chromosome 13q33-34 with 23 
exons (Liang, Fei et al. 1995). Since the mammalian PEPT1 protein crystal 
structure has not been characterized yet, it was predicted by computational 
modeling to consist of 12 putative transmembrane spanning domains (TMDs) 
with a large extracellular loop between the ninth and tenth TMDs, two putative 
protein kinase C-dependent phosphorylation sites and both the C- and N-termini 
face to the cytosol (Daniel and Kottra 2004; Rubio-Aliaga and Daniel 2008). The 
first 4 and 7-9 transmembrane domains were revealed to determine the substrate 
affinity and binding characteristics (Doring, Will et al. 1998; Terada, Saito et al. 
2000; Doring, Martini et al. 2002; Rubio-Aliaga and Daniel 2008). 
 
Pharmacogenomics of PEPT1 
Over 40 coding single nucleotide polymorphisms (SNPs) and about 100 
haplotypes of human PEPT1 gene have been identified (Zair, Eloranta et al. 2008; 
Sugiura, Umeda et al. 2013). Nine nonsynonymous and four synonymous coding-
region SNPs were first reported by Zhang and coworkers and followed by 
functional analysis in heterologously transfected HeLa cells (Zhang, Fu et al. 
2004). They found all PEPT1 nonsynonymous variants identified have conserved 
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substrate recognition, when compared with the reference PEPT1, although one 
rare variant P586L (i.e., SNP 1758C>T) showed significantly reduced GlySar 
uptake and may affect PEPT1 expression as demonstrated by protein analysis in 
vitro. In another study, 350G>A (S117N) and 1256G>C (G419A) were found to 
be the most common PEPT1 SNPs (Anderle, Nielsen et al. 2006). These two 
SNPs along with other six genetic variants were also tested for the transport of 
several PEPT1 substrates but no significant alternation was observed except for 
the SNP 83T>A (F28Y). This variant displayed significantly reduced uptake of 
cephalexin attributable to lower substrate affinity (i.e., increased Km). As to the 
pharmaceutical and pharmacokinetic relevance of PEPT1 SNPs, little is known 
currently and further studies are still needed. Collectively, a low level of PEPT1 
genetic polymorphisms has been found in human. 
 
Tissue Distribution and Cellular Localization of PEPT1 
PEPT1 was found to be expressed in a variety of tissues with primary 
expression in small intestine in mammals. Specifically, PEPT1 is localized at the 
brush border membrane of intestinal epithelial cells in villi tips, but not other cells 
in the crypts (Ogihara, Saito et al. 1996; Walker, Thwaites et al. 1998; Groneberg, 
Doring et al. 2001).  The abundant mRNA expression of PEPT1 has been detected 
in small intestine of several mammalian species including human (Liang, Fei et al. 
1995; Herrera-Ruiz, Wang et al. 2001; Englund, Rorsman et al. 2006; Meier, 
Eloranta et al. 2007), rabbit (Fei, Kanai et al. 1994), rat (Miyamoto, Shiraga et al. 
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1996; Shen, Smith et al. 1999; Howard, Goodlad et al. 2004; Lu and Klaassen 
2006) and mouse (Lu and Klaassen 2006; Jappar, Wu et al. 2010). The 
predominant protein expression of PEPT1 was also detected and in agreement 
with its mRNA levels in small intestine (Ogihara, Saito et al. 1996; Shen, Smith et 
al. 1999; Jappar, Wu et al. 2010). However, the colonic expression of PEPT1 is 
still under debate since some contradictory studies have been published. Some 
researchers have observed PEPT1 protein expression in normal mouse, rat and 
human colon (Ziegler, Fernandez-Estivariz et al. 2002; Ford, Howard et al. 2003; 
Wuensch, Schulz et al. 2013), whereas others could not detect PEPT1 protein in 
normal colon (Ogihara, Saito et al. 1996; Shen, Smith et al. 1999; Groneberg, 
Doring et al. 2001; Merlin, Si-Tahar et al. 2001; Jappar, Wu et al. 2010).  
Apart from the intestine, PEPT1 was also detected in S1 segments of renal 
proximal tubule in the kidney and localized on the apical membrane of renal 
epithelial cells (Fei, Kanai et al. 1994; Liang, Fei et al. 1995; Saito, Okuda et al. 
1995; Miyamoto, Shiraga et al. 1996; Smith, Pavlova et al. 1998; Shen, Smith et 
al. 1999; Daniel and Kottra 2004; Lu and Klaassen 2006).  The functional activity 
of PEPT1 in kidney was studied due to its renal expression. Studies using Pept2 
knockout mice indicated that PEPT1 was less important than PEPT2 in terms of 
renal reabsorption of the peptide-bound amino nitrogen and peptidomimetic drugs 
(Ocheltree, Shen et al. 2005; Shen, Ocheltree et al. 2007). 
Other tissues including liver, pancreas, lung, bile duct, ovary, placenta, 
testis, prostate, mammary gland, nasal epithelium, and placenta, have been 
reported to express modest or low level of PEPT1 mRNA (Herrera-Ruiz, Wang et 
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al. 2001; Knutter, Rubio-Aliaga et al. 2002; Lu and Klaassen 2006; Agu, Cowley 
et al. 2011; Sun, Tan et al. 2013). However, the functional role of PEPT1 in these 
tissues was little known and lack of investigation. 
 
Transport mechanism of PEPT1 
The fundamental cellular transport mechanism of PEPT1 has been 
delineated by numerous functional experimental studies as well as computational 
modeling for the last decades (Fei, Kanai et al. 1994; Mackenzie, Fei et al. 1996; 
Mackenzie, Loo et al. 1996; Amasheh, Wenzel et al. 1997; Nussberger, Steel et al. 
1997; Kottra, Stamfort et al. 2002; Daniel 2004; Irie, Terada et al. 2005).  In 1983, 
Ganapathy et al. offered the first evidence that indicate intestinal dipeptide uptake 
is driven by an inwardly directed proton gradient (Ganapathy and Leibach 1983). 
Now it has been demonstrated that PEPT1 uses a proton electrochemical gradient 
and negative membrane potential as its driving force to mediate the cellular 
uptake of peptides/peptidomimetics (Boll, Markovich et al. 1994; Fei, Kanai et al. 
1994; Daniel 1996; Nussberger, Steel et al. 1997; Daniel 2004). By employing 
two-microelectrode voltage-clamp in cRNA-injected oocytes with dipeptide 
glycyl-sarcosine (GlySar) as the characterizing substrate, an ordered and 
simultaneous transport model has been suggested to describe the transport 
features of PEPT1 (Mackenzie, Loo et al. 1996), in which the transporter was first 
bound to proton under outward facing conformation with change of substrate-
binding affinity. Then, PEPT1 started to translocate the substrate through a 
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conformational change once binding to the substrate molecule. Similar models 
were proposed including a symmetry proton binding intra- and extracellular 
model with focus on intracellular binding event (Nussberger, Steel et al. 1997). 
Based on their experimental results and previous studies, Irie et al. have 
developed a computational model to illustrate the proton-coupled transport 
mechanism of PEPT1 with two key hypotheses: (1) H
+
 binds to both the H
+
-
binding site and the substrate-binding site; and (2) H
+
 at the substrate binding site 
is essential for the interaction of anionic substrates, but could inhibit that of 
neutral and cationic substrates (Irie, Terada et al. 2005).  
In mammalian cells, the proton gradient driving force was found to be 
generally provided and maintained by the activity of electro-neutral proton-cation 
exchangers (i.e., Na
+
/H
+
 antiporters) (Daniel 1996; Adibi 1997; Nussberger, Steel 
et al. 1997). For example, Thwaites has demonstrated that the activity of Na
+
/H
+
 
exchanger (NHE3) on the apical membrane, but not basolateral membrane 
(NHE1), increased after GlySar was added in Caco-2 cells (Thwaites, Ford et al. 
1999). Other evidence also showed that when NHE3 activity was blocked, the 
transport activity of PEPT1 was significantly influenced (Kennedy, Leibach et al. 
2002; Thwaites, Kennedy et al. 2002; Watanabe, Kato et al. 2005). The Na
+
-K
+
- 
ATPase at the basolateral membrane of epithelial cells is identified to generate 
inwardly directed sodium gradient and maintain the intracellular sodium balance 
with apical Na
+
/H
+
 antiporter. Figure 2.2 (adopted from Daniel 1996) provides a 
schematic model of the proposed translocation mechanism for PEPT1.  
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Regard to the electrogenic transport of PEPT1, the neutral substrates are 
preferred by PEPT1 and translocated with a 1:1 stoichiometry in proton to 
substrate flux. Generally, PEPT1 will have higher activity when transporting 
anionic substrates at more acidic microclimate and when transporting cationic 
substrates at more neutral or slightly alkaline extracellular pH (Amasheh, Wenzel 
et al. 1997; Steel, Nussberger et al. 1997).  
 
Substrate Specificity 
It has been accepted that PEPT1 has exceptionally broad substrate 
specificity that covers hundreds of di-/tri-peptides and peptide-like drugs (Rubio-
Aliaga and Daniel 2002; Daniel and Kottra 2004; Terada and Inui 2004).  First of 
all, as a nutrient transporter, PEPT1 is capable to transport up to 400 dipeptides 
and 8000 tripeptides that are naturally occurring oligopeptides derived from 
dietary protein breakdown products (Daniel 2004; Daniel and Kottra 2004). 
However, not all the di-/tri-peptides are substrates of PEPT1 that have to meet 
certain criteria. For example, PEPT1 has preferences to transport peptides with L-
-amino acid residues to its D-isomers (Daniel, Morse et al. 1992). Another 
typical structure requirement for PEPT1 substrate is summarized as two 
oppositely charged head groups separated with a distance between 500 to 635 pm 
(Rubio-Aliaga and Daniel 2008). Based on numerous uptake and inhibition 
experiments, Rubio-Aliaga et al. summarized a few structure features that a 
typical di-/tri-peptide substrate of PEPT1 and PEPT2 should possess:1) L-amino 
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acids, 2) an acidic or hydrophobic group at C-terminus, 3) a weakly basic group in 
-position at N-terminus, 4)  a ketomethylene or acid amide bond, and 5) a trans 
conformation of peptide bonds (Rubio-Aliaga and Daniel 2008). 
Aside from a wide array of di-/tri-peptides, PEPT1 is also capable of 
transporting many peptidomimetic drugs with variety in structure, molecular size, 
polarity, net charge, and stereochemistry. These pharmacological active 
compounds, which were demonstrated as PEPT1 substrates, include β-lactam 
antibiotics (e.g., ceftibuten, cephalexin, cefixime and cefadroxil), angiotensin 
converting enzyme inhibitors (e.g., captopril, enalapril, and fosinopril), antitumor 
drug bestatin, antiviral nucleoside prodrugs (e.g., valacyclovir, valganciclovir) 
and the photodynamic therapy agent 5-aminolevulinic acid.  
Therefore, PEPT1 was viewed as an excellent oral drug delivery target due 
to its broad substrate specificity, high transport capacity and abundant expression 
in the small intestine. It should be noted that, with further research, the number of 
pharmacologically relevant compounds transported by PEPT1 will increase given 
that prodrug strategies which aim at PEPT1 have been employed to improve oral 
bioavailability of poorly absorbed drugs. Novel compounds such as zanamivir, 
oseltamivir and didanosine prodrugs have been developed recently that target 
PEPT1 as a drug transporter (Gupta, Gupta et al. 2011; Yan, Sun et al. 2011; 
Brandsch 2013; Gupta, Varghese Gupta et al. 2013). 
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Regulation of PEPT1 
The expression or functional activity of PEPT1 has been shown to be 
regulated via a variety of mechanisms under varying conditions. Understanding 
the underlying mechanisms of PEPT1 regulation is essential to comprehending its 
role as mediator of nutritional and pharmacological substrate absorption. Factors 
such as diet, hormone, pathological conditions, and other exogenous stimuli have 
been demonstrated to affect the PEPT1 expression or transport activity. The 
mechanisms responsible for these regulations could be specified as transcriptional, 
translational, post-translational regulation of PEPT1 gene, or other unknown 
mechanisms. 
Hormones such as insulin, leptin, growth hormone, and thyroid hormone 
are able to regulate PEPT1 abundance and activity in epithelial cells 
(Thamotharan, Bawani et al. 1999; Buyse, Berlioz et al. 2001; Ashida, Katsura et 
al. 2002; Sun, Zhao et al. 2003; Sun, Zhao et al. 2003). These hormones appear to 
increase the PEPT1 protein density on the apical membrane by recruitment of 
preformed transporters, therefore increasing the Vmax (but not Km) of PEPT1-
mediated transport. As an acute regulation, PEPT1 activity was also found to be 
inhibited by protein kinase A (PKA) and protein kinase C (PKC), as well as their 
upstream molecules such as cAMP (Muller, Brandsch et al. 1996; Berlioz, Julien 
et al. 1999). 
The PEPT1 promoter has been analyzed and several transcription factors 
were identified to be responsible for the transcriptional regulation of PEPT1. Sp1 
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was found to work on PEPT1 promoter through direct binding to the GC-rich 
region (Shimakura, Terada et al. 2005). Further studies revealed another specific 
transcription factor, caudal-related homeobox protein 2 (Cdx 2), is responsible for 
activating intestine-specific PEPT1 expression through cooperation with Sp1 and 
binding to the Cdx 2 responsive element (Shimakura, Terada et al. 2006). 
Dalmasso et al. also provided an evidence, for first time, that PEPT1 expression 
was regulated at a posttranscriptional level by miRNAs in intestinal epithelial 
cells (Dalmasso, Hang et al. 2011).  
Several studies have demonstrated that the expression level of PEPT1 and 
its function is affected by dietary treatments. The mRNA and protein expressions 
of PEPT1 could be induced by several folds when incubating dipeptide GlySar in 
in Caco-2 cells (Thamotharan, Bawani et al. 1998). In rat, either fasting or feeding 
with dietary protein as well as peptides has been shown to increase the expression 
level of PEPT1 and its transport activity (Shiraga, Miyamoto et al. 1999; 
Thamotharan, Bawani et al. 1999). Ma et al. also demonstrated that 16 h of fasting 
can cause significant upregulation of PEPT1 protein expression in the murine 
small intestine and translating into a significant increase in oral absorption of 
GlySar (Ma, Hu et al. 2012). 
Many physiological factors such as disease state, diurnal rhythm and 
development were also proved to be associated with PEPT1 expression and its 
functional activity. For example, PEPT1 is expressed throughout the small 
intestine but virtually absent in the colon under normal physiological conditions. 
However, under inflammatory conditions (e.g., short-bowel syndrome, chronic 
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ulcerative colitis and Crohn’s disease), PEPT1 is aberrantly expressed in colon 
tissues (Merlin, Si-Tahar et al. 2001; Dalmasso, Garg et al. 2007; Zucchelli, 
Torkvist et al. 2009). 
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5-AMINOLEVULINIC ACID 
Introduction 
5-Aminolevulinic acid (5-ALA or -Aminolevulinic acid or ALA) is a 
naturally occurring intermediate compound that normally formed in the 
mitochondria in the early stage of heme biosynthetic pathway. Through several 
metabolism steps, eight 5-ALA molecules can conjugate together to yield 
protoporphyrin IX (PpIX) and finally converts into heme. Protoporphyrin IX, the 
precursor of heme, is a potent photosensitizer that is widely applied in the 
photodynamic therapy (PDT) and fluorescence diagnosis (FD) in dermatology, 
urology, neurosurgery, Otorhinolaryngology, gynecology and gastroenterology. 
For the last two decades a substantial amount of studies have been focused on the 
clinical application of 5-ALA as a prodrug in PDT and elucidation of the 
mechanism of ALA-PDT.(Peng, Berg et al. 1997; Peng, Warloe et al. 1997; Kelty, 
Brown et al. 2002; Krammer and Plaetzer 2008) 
  The chemical structures of 5-ALA and its metabolite PpIX were shown 
in Figure 2.3. 5-ALA is a small polar molecule with molecular weight of 131.1. 
At physiological pH it exists mainly as a charged zwitterion, which accounts for 
its low lipid solubility. The pKa1 and pKa2 are 4.1 and 8.7, respectively (Uehlinger, 
Zellweger et al. 2000).   
In the following section, current knowledge about pharmacokinetics, 
transport mechanism of 5-ALA and its application in photodynamic therapy were 
discussed. 
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Application of 5-ALA in Photodynamic Therapy 
Photodynamic therapy (PDT) is a promising and minimally invasive 
therapeutic treatment for various cancers and non-malignant diseases. One of the 
major advantages of PDT over other anticancer treatment modalities is its high 
degree of selectivity. This is typically accomplished via the systemic 
administration of a non-toxic photosensitizing agent, which can accumulate in 
target tumor tissues, and subsequent illumination of the tumor site with visible 
light for photo-activation (Figure 2.4). The excited photosensitizer contributes to 
the generation of intracellular singlet oxygen and other reactive oxygen species, 
which results in the tumor cell damage (Cox, Krieg et al. 1982; Cox and Whitten 
1982; Dickson and Pottier 1995; Peng, Berg et al. 1997; Peng, Warloe et al. 1997). 
Besides oxidative cytotoxicity induced in PDT, the vascular shutdown and local 
inflammatory reaction also are recognized to contribute to the overall PDT effect 
(Dougherty, Gomer et al. 1998; Castano, Mroz et al. 2008; Garg, Nowis et al. 
2010; Firczuk, Winiarska et al. 2011). 
There are many types of photosensitizers available and several routes 
(topical, oral, or intravenous) by which they can be delivered to the patient. 
Additional selectivity of PDT may be achieved by the administration of a 
photosensitizer precursor. One clinically approved example of such a compound 
is 5-ALA, a precursor of the natural photosensitizer PpIX. As a photosensitizer 
prodrug for PDT, 5-ALA has no intrinsic photochemical properties, but its 
metabolite PpIX is an ideal photosensitizing agent which is non-toxic, 
biologically stable, photodynamically active and selectively retained in the target 
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tissue. Once exogenous 5-ALA is administered topically or systemically, it will 
be quickly converted into active photosensitizer PpIX through several 
biochemical reactions in the heme biosynthesis pathway. It has been found that 
differential enzymes activity and limited availability of iron in tumor cells 
compared to normal tissues finally leads to a higher accumulation of PpIX within 
tumor cells. When PpIX concentration reaches the therapeutic level in the target 
tissue, subsequent exposure to visible light will activates PpIX and consequently 
triggers the oxidative cytotoxicity (Peng, Berg et al. 1997; Peng, Warloe et al. 
1997; Krammer and Plaetzer 2008; Wachowska, Muchowicz et al. 2011). 
5-ALA also serves as a photodynamic agent for fluorescence diagnosis 
(FD) and fluorescence-guided resection of malignant and non-malignant diseases 
in clinical practice. Many clinical studies using ALA for FD have suggested “this 
technique is more efficient than white cystoscopy as the contrast is enhanced” 
(Jichlinski, Wagnieres et al. 1997; Jichlinski, Wagnieres et al. 1997; Datta, Loh et 
al. 1998; Kelty, Brown et al. 2002; Krammer and Plaetzer 2008). The distinct 
wavelength chosen for irradiation causes different outcome (i.e., near 400 nm can 
induce fluorescence for FD and 635 nm can produce physic-chemical reaction for 
PDT).  
During the last two decades numerous researches have been focused on 
the 5-ALA and its therapeutic application in ALA-PDT and ALA-FD. In 1987, 5-
ALA was employed, for the first time, in photodynamic therapy of 
erythroleukaemic cells as a photosensitizing agent (Malik and Lugaci 1987). In 
the same year Qian et al. showed the results of the porphyrin accumulation and 
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fluorescence in tumors and other tissues 24h post intraperitoneal injection of ALA 
in mice (Qian, Evensen et al. 1987). In 1990 Kennedy and Pottier reported the 
earliest clinical trial with ALA-PDT for superficial basal cell carcinomas 
(Kennedy and Pottier 1992). Thereafter, the systematic and topical application of 
ALA in clinical practice was growing rapidly and attracted a large body of 
research in this field. Currently, ALA and its esters has been approved by US 
FDA as a promising treatment of several malignant and premalignant conditions 
such as actinic keratosis, basal cell carcinoma, Bowen’s disease, bladder cancer 
and others. In Europe, 5-ALA has been approved for intraoperative photodynamic 
diagnosis of residual malignant glioma while methyl-ester and hexyl-ester 
derivatives of 5-ALA have been approved for treatment of basal cell carcinoma 
and actinic keratosis and diagnostic application of bladder cancer, respectively 
(Dolmans, Fukumura et al. 2003; Fotinos, Campo et al. 2006; Krammer and 
Plaetzer 2008; Nokes, Apel et al. 2013).  In summary, information about currently 
approved 5-ALA products and their application was provided in Table 2.2. 
 
Heme Biosynthesis Pathway 
5-ALA is an endogenous compound that can be found in the body 
naturally. As we know, there are a number of substrates and enzymes involved in 
the heme biosynthesis pathway (Figure 2.5). The initial and rate-limiting step in 
this pathway is the synthesis of 5-ALA. ALA is normally synthesized by the 
condensation of glycine and succinyl-CoA in mitochondria that is catalyzed by 
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ALA synthase (ALAS) and affiliated by pyridoxal-5-phosphate (PLP) as a 
cofactor (Ajioka, Phillips et al. 2006).  After transferring from inside of the 
mitochondria to cytosol, two molecules of ALA are condensed to yield 
porphobilinogen (PBG) with the aid of zinc-dependent enzyme-aminolevulinate 
dehydratase (ALAD). After a series of intermediate biochemical reaction, four 
molecules of PBG can form a linear and unstable tetrapyrolle called 
hydroxymethylbilane (HMB) in a head-to-tail manner. This reaction is a rate-
limiting step which is catalyzed by uroporphyrin I synthase. Hydroxymethylbilane 
can then convert into uroporphyrinogen III using uroporphyrinogen III synthase 
(URO3S) as a major route, as well as undergo spontaneous cyclization that leads 
to the formation of uroporphyrinogen III. Uroporphyrinogen decarboxylase 
(UROD) catalyzes decarboxylation of uroporphyrinogen III to yield 
coproporphyrinogen III which is transported back to the inter-membrane space of 
mitochondria. The next intermediate in this pathway, protoporporphyrinogen IX, 
is synthesized from coproporphyrinogen III under catalyzation of 
Coproporphyrinogen oxidase (CPO) and soon oxidized into protoporphyrin IX 
(PpIX) by removal of six hydrogens. The final product, heme, is formed via the 
insertion of an iron into the center of PpIX (Fukuda, Casas et al. 2005; Ishizuka, 
Abe et al. 2011; Wachowska, Muchowicz et al. 2011). 
 
Pharmacokinetics of 5-ALA  
The endogenous 5-ALA level in the body has been determined by several 
studies. Fauteck et al. reported the endogenous 5-ALA plasma concentration in 
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human was 11.2 g/L (Fauteck, Ackermann et al. 2008). Similarly, Dalton et al. 
also reported the endogenous 5-ALA plasma concentrations were 28 ± 18 g/L 
(mean ± S.D.) in a clinical pharmacokinetic study (Dalton, Yates et al. 2002). The 
endogenous plasma concentrations of 5-ALA were around 1.5 g/L and 25g/L 
in rat and dog, respectively (Dalton, Meyer et al. 1999; Tahara, Tanaka et al. 
2007). 5-ALA was also detected by Gorchen et al in cerebrospinal fluid with a 
range from 6 to 36 nmol/L (Gorchein and Webber 1987).  
5-ALA has been shown to be rapidly eliminated from the human body, 
with a plasma half-life of 50 min when given intravenously and 45 min when 
given orally (Dalton, Yates et al. 2002). Systemic administration of 5-ALA was 
followed by clearance via the liver, bile and kidney. The small volume of 
distribution of 9.3 L indicates that a large portion was excreted unchanged in the 
urine and eliminated by first-pass metabolism (Dalton, Yates et al. 2002). Good 
oral bioavailability (> 50%) of 5-ALA was shown in human and dog (van den 
Boogert, van Hillegersberg et al. 1998; Dalton, Meyer et al. 1999; Dalton, Yates 
et al. 2002). A study on the plasma protein binding of 5-ALA showed that protein 
binding was 12% in human in the range of 500 to 5000 µg/L. The fluorescence 
microscopy of tissue samples revealed peak concentration of PpIX was achieved 
at 4 to 6 h after oral administration of  5-ALA (Loh, MacRobert et al. 1993). And 
intracellular PpIX returns to background levels within 24 to 48 hours post 
application. 
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Transport mechanism of 5-ALA 
The mechanism of 5-ALA transport into the cells and its disposition in 
normal as well as malignant tissues has intrigued research interests and been 
investigated for a long time since 5-ALA was applied as a photosensitizer in 
photodynamic therapy. Numerous uptake and transport studies have identified 
several distinct carrier-mediated transport systems which are involved in the 
translocation of 5-ALA.  
In 1998, Daniel group demonstrated, for first time, that 5-ALA uses the 
peptide transporters PepT1 and PepT2 for entering into epithelial cells through 
uptake studies in Xenopus laevis oocytes and yeast cells (Doring, Walter et al. 
1998). Although it does not possess a typical peptide bond in the narrower sense 
but a ketomethylene group, 5-ALA shares similar structure with a dipeptide 
GlySar which is a substrate for PepT1 and PepT2. Having shown earlier that 
PepT1 is also expressed in the extra hepatic biliary duct, Neumann et al. 
characterized the transport of 5-ALA in bile duct tumor cells and discussed that 5-
ALA could be accumulated in such cells via PepT1 before photodynamic tumor 
therapy (Neumann and Brandsch 2003). In 2013, Chung et al. confirmed both the 
expression of PepT1 in cholangiocyte cell lines derived from bile duct carcinoma 
and the transport of 5-ALA via PepT1 in these cells (Chung, Kim et al. 2013). 
Moreover, Hagiya et al. found that high expression of PepT1 and low expression 
of the ATP-binding cassette transporter ABCG2 (a porphyrin efflux transporter) 
together determined the 5-ALA-induced protoporphyrin IX production and the 
effective photocytotoxicity in gastric and bladder cancer cells. Evaluation of the 
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expression levels of PepT1 and ABCG2 genes could be useful to predict the 
efficacy of 5-ALA-based photodynamic therapy (Hagiya, Endo et al. 2012; 
Hagiya, Fukuhara et al. 2013). 
5-ALA was also reported to be a substrate of peptide transporter PepT2 
(Doring, Walter et al. 1998; Novotny, Xiang et al. 2000; Ennis, Novotny et al. 
2003). Recently Smith group explored the pivot role of PepT2 in modulating 5-
ALA concentrations in CNS and found PepT2 can significantly influence 5-ALA 
pharmacokinetics and pharmacodynamics with genetically-modified mouse model 
(Ocheltree, Shen et al. 2004; Hu, Shen et al. 2007; Kamal, Keep et al. 2008). 
Besides PepT1 and PepT2, the results of certain in vitro studies also 
supported the involvement of other transporters in facilitating 5-ALA entering 
into cells.  Rud et al. showed that -aminobutyric acid (GABA) and several amino 
acids inhibited 5-ALA uptake in several cell lines, and the uptake increased in a 
Na
+
- and Cl
-
-dependent manner (Rud, Gederaas et al. 2000). Similar observations 
from Bermudez et al. also suggested that Na
+
- and Cl
-
-dependent neurotransmitter 
transporters (or BETA transporters) may take up 5-ALA into murine mammary 
adenocarcinoma cells (Bermudez Moretti, Correa Garcia et al. 2002). A recent 
study found specifically that the expression of SLC6A6 and SLC6A13, members 
of BETA transporters, increased the 5-ALA uptake, resulting in enhanced 5-ALA-
induced photodamage in cancerous cells (Tran, Mu et al. 2014). In addition to 
neurotransmitter transporters, other investigators have shown that proton-coupled 
amino acid transporter PAT1 (SLC36A1) was able to recognize and transport 5-
ALA in PAT1-expressing Xenopus laevis oocytes and Cos-7 cells (Anderson, 
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Jevons et al. 2010; Frolund, Marquez et al. 2010). In conclusion, several carrier-
mediated transport systems of 5-ALA identified and investigated in mammals 
were summarized in Table 2.3. 
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FIGURES AND TABLES 
 
 
 
Figure 2.1 Overview of protein digestion and absorption in the gastrointestinal 
tract. (1) Brush-border peptidases; (2) brush-border amino-acid transport systems; 
(3) brush-border peptide transport system; (4) cytoplasmic peptidases; (5) 
basolateral amino acid transport systems; (6) basolateral peptide transport 
system(s). GI, gastrointestinal. (Adopted from Ganapathy et al. Protein digestion 
and absorption. Chapter 65, Physiology of the gastrointestinal tract, fourth edition.) 
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Figure 2.2 Schematic model of PEPT1-mediated cellular transport in intestinal 
epithelial cells (Adopted from Daniel 1996). 
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Figure 2.3 Chemical structures of 5-Aminolaevulinic acid (5-ALA) and 
protoporphyrin IX (PpIX). 
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Figure 2.4 Overview of photodynamic therapy mechanism. (Adopted from 
Wachowska, Muchowicz et al. 2011) 
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Figure 2.5 5-ALA in the major route of heme biosynthesis pathway. (Adopted 
from Wachowska, Muchowicz et al. 2011) 
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Table 2.1 The proton-coupled oligopeptide transporter family (SLC15) 
Human gene 
name 
Protein 
name 
Aliases Predominant 
substrates 
Transport 
type/ 
coupling 
ions 
Tissue distribution and cellular/ 
subcellular expression 
Human 
gene locus 
Protein 
length (a.a.) 
 
SLC15A1 PepT1 Oligopeptide 
transporter 
1, H+-peptide 
transporter 1 
Di- and 
tripeptides, 
protons, 
beta-lactam 
antibiotics 
C/H+ Apical surface of epithelial cells 
from small intestine and 
kidney; pancreas, bile duct and 
liver 
13q32.3 Human 708 
Mouse 709 
Rat 710 
 
SLC15A2 PepT2 Oligopeptide 
transporter 
2, H+-peptide 
transporter 2 
Di- and 
tripeptides, 
protons, 
beta-lactam 
antibiotics 
C/H+ Apical surface of epithelial cells 
from kidney and choroid 
plexus; neurons, astrocytes 
(neonates), lung, mammary 
gland, spleen, enteric nervous 
system 
3q21.1 Human 729 
Mouse 729 
Rat 729 
SLC15A3 PhT2 Peptide/ 
histidine 
transporter 
2, PTR3 
Di- and 
tripeptides, 
protons, 
histidine 
C/H+ Lung, spleen, thymus, intestine 
(faintly in brain, liver, adrenal 
gland, heart) 
11q12.2 Human 577 
Mouse 574 
Rat 572 
SLC15A4 PhT1 Peptide/ 
histidine 
transporter 
1, PTR4 
Di- and 
tripeptides, 
protons, 
histidine 
C/H+ Brain, eye, intestine (faintly in 
lung and spleen) 
12q24.32 Human 581 
Mouse 578 
Rat 582 
 
References:  
(Herrera-Ruiz and Knipp 2003; Daniel and Kottra 2004; Smith, Clemencon et al. 
2013) 
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Table 2.2 Approved 5-ALA products and their application 
 
Generic 
name 
Chemical name Approval Applications 
Activation 
wavelength 
Levulan 
5-Aminolevulinic 
acid 
EU, USA 
Actinic keratosis, basal-cell 
carcinoma, head and neck, 
and gynaecological tumors 
 
Diagnosis of brain, head and 
neck, and bladder tumors 
 
635 nm 
 
 
375–400 
nm 
Gilolan 
5-Aminolevulinic 
acid 
EU 
Intraoperative photodynamic 
diagnosis of residual glioma 
400–410 nm 
Metvix 
Methyl 5-
Aminolevulinic acid 
EU, Australia 
Actinic keratoses, basal-cell 
carcinoma 
635 nm 
Hexvix 
Hexyl 5-
Aminolevulinic acid 
EU Diagnosis of bladder tumors 375–400 nm 
Benzvix 
Benzyl 5-
Aminolevulinic acid 
In clinical trials Gastrointestinal cancer 635 nm 
 
References: 
(Dolmans, Fukumura et al. 2003) 
(Krammer and Plaetzer 2008) 
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Table 2.3 Transporters involved in the transport of 5-ALA  
 
Transporter Alias 
Animal 
species 
Experimental system Reference 
PEPT1 
(SLC15A1) 
Solute Carrier Family 
15 Oligopeptide 
Transporter Member 1 
Human 
cRNA-injected XLO, cDNA-
transfected yeast cells, bile 
duct tumor cells, gastric and 
bladder tumor cells, cDNA-
transfected MDCK cells, 
Caco-2 cells 
(Doring, Walter et al. 1998; 
Neumann and Brandsch 2003; 
Anderson, Jevons et al. 2010; 
Frolund, Marquez et al. 2010; 
Hagiya, Endo et al. 2012; 
Chung, Kim et al. 2013; 
Hagiya, Fukuhara et al. 2013)  
PEPT2 
(SLC15A2) 
Solute Carrier Family 
15 Oligopeptide 
Transporter Member 2 
Human,  
Mouse, 
Rat 
cRNA-injected XLO, cDNA-
transfected yeast cells, rat CP 
epithelial cells,  PepT2 
knockout mice 
(Doring, Walter et al. 1998; 
Novotny, Xiang et al. 2000; 
Ennis, Novotny et al. 2003; 
Ocheltree, Shen et al. 2004; 
Hu, Shen et al. 2007) 
PAT1 
(SLC36A1) 
Proton-coupled 
Amino Acid 
Transporter 1 
Human 
cRNA-injected XLO, cDNA-
transfected COS-7 cells, 
Caco-2 cells 
(Anderson, Jevons et al. 2010; 
Frolund, Marquez et al. 2010) 
TAUT 
(SLC6A6) 
 
GAT2 
(SLC6A13) 
Sodium- and 
Chloride-Dependent 
Taurine Transporter 
 
Sodium- and 
Chloride-Dependent 
GABA Transporter 2 
Human,  
Mouse 
murine mammary 
adenocarcinoma cells, human 
colon cancer cells, human 
cervical cancer HeLa cells 
(Rud, Gederaas et al. 2000; 
Bermudez Moretti, Correa 
Garcia et al. 2002; Tran, Mu et 
al. 2014) 
 
XLO, Xenopus laevis oocytes 
MDCK, Madin-Darby canine kidney 
CP, choroid plexus  
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CHAPTER 3                                                                                  
SIGNIFICANCE OF PEPT1 IN THE IN SITU INTESTINAL 
PERMEABILITY OF 5-AMINOLEVULINIC ACID IN WILDTYPE AND 
PEPT1 KNOCKOUT MICE 
 
ABSTRACT 
PURPOSE: To determine the role of peptide transporter PepT1 in the intestinal 
absorption of the photodynamic therapy agent 5-aminolevulinic acid (5-ALA) in 
wildtype and PepT1 knockout mice.   
METHODS: In situ single-pass intestinal perfusions were performed in the 
duodenum, jejunum, ileum and colon of wildtype and PepT1 knockout mice at 10 
µM [
14
C]5-ALA. 5-ALA effective permeability (Peff) was evaluated at steady-
state in pH 6.5 buffer for 90 min using inulin as a marker for water flux 
corrections. Inhibition studies were performed in the jejunum of wildtype mice 
with radiolabeled 5-ALA and 25 mM of the potential inhibitors glycylsarcosine 
(GlySar), cefadroxil, L-histidine, L-proline, -alanine, tetraethylammonium (TEA) 
and p-aminohippuric acid (PAH). Concentration-dependent studies were also 
performed in the jejunum of wildtype mice using 0.01-50 mM of radiolabeled 5-
ALA.
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RESULTS: The Peff of 5-ALA in wildtype mice was determined as 1.65×10
-4
 
cm/s in duodenum, 1.91×10-4 cm/s in jejunum, 1.20×10-4 cm/s in ileum and 
0.14×10-4 cm/s in colon.  The Peff of 5-ALA in the duodenum, jejunum, and ileum 
of PepT1 knockout mice was only about 10% of that in wildtype animals. Colonic 
Peff values were very small and not different between the two genotypes. 5-ALA 
jejunal permeability was substantially reduced in the presence of GlySar (residual 
of 31%) and cefadroxil (residual of 16%). In contrast, the Peff of 5-ALA was not 
altered when co-perfused with L-histidine, L-proline, -alanine, TEA or PAH. 
The jejunal uptake of 5-ALA exhibited a saturable profile that was best described 
by Michaelis-Menten kinetics, where Vmax' = 2.30 nmol/cm
2
/sec and Km' = 13.4 
mM when referenced to inlet perfusate concentrations. When referenced to 
intestinal wall concentrations, the intrinsic absorption parameters were estimated 
as Vmax = 1.89 nmol/cm
2
/sec and Km = 3.74 mM.  
CONCLUSION:  These findings indicate that the intestinal uptake of 5-ALA is 
primarily mediated by PepT1, which accounts for about 90% of its permeability 
in mouse small intestine. The different segmental permeability of 5-ALA was 
consistent with PepT1 expression along the intestinal segments. The contribution 
of other transporters, including PAT1, in mediating the intestinal permeability of 
5-ALA is minor at best. 
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INTRODUCTION 
 Photodynamic therapy (PDT) is a promising and minimally invasive 
therapeutic modality for the treatment of various cancers and non-malignant 
diseases (Nokes, Apel et al. 2013). PDT involves two critical components (i.e., a 
certain wavelength of light and a photosensitive molecule) that combine to trigger 
oxidative cytotoxicity in target cells and/or tissues (Dolmans, Fukumura et al. 
2003). 5-Aminolevulinic acid (5-ALA), a naturally occurring intermediate in the 
heme biosynthesis pathway, is widely applied as a prodrug in photodynamic 
therapy and photodynamic detection (Peng, Berg et al. 1997; Peng, Warloe et al. 
1997; Kelty, Brown et al. 2002; Krammer and Plaetzer 2008). Although 5-ALA 
itself has no intrinsic photochemical properties, its metabolite protoporphyrin IX 
(PpIX) is an ideal photosensitizer which is non-toxic, biologically stable, 
photodynamically active and selectively retained in the target tissue. The 
mechanism of 5-ALA based PDT has been elucidated and applied in clinical 
practice (Wachowska, Muchowicz et al. 2011; Colditz and Jeffree 2012; Colditz, 
Leyen et al. 2012). Briefly, after exogenous 5-ALA is administered topically or 
systemically, it will be quickly converted into active photosensitizer PpIX through 
several enzymatic reactions in the heme biosynthesis pathway. The selective 
accumulation of PpIX within tumor cells, which reduces nonspecific tissue 
toxicity, is a unique advantage in the PDT and fluorescence diagnosis of solid 
tumors (e.g., malignant glioma, bladder cancer, etc.). It has been found that the 
differential enzyme activity and limited availability of iron in tumor cells, 
compared to normal tissues, contribute to the relatively specific accumulation of  
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PpIX within tumor cells (Navone, Polo et al. 1990; Stout and Becker 1990). 
However, the transport mechanism of 5-ALA into cells, which may partially 
explain the tumor selectivity of ALA-PDT, is poorly studied and unclear. In 
clinical practice, a high background accumulation after oral administration of 5-
ALA has been reported in normal enterocytes (Loh, MacRobert et al. 1993; 
Regula, MacRobert et al. 1995). In addition, a remaining question concerns how 
the hydrophilic 5-ALA is absorbed from the gastrointestinal tract lumen into the 
systemic circulation system given good oral bioavailability of 5-ALA shown in 
several experimental and clinical studies (van den Boogert, van Hillegersberg et al. 
1998; Dalton, Meyer et al. 1999; Dalton, Yates et al. 2002). 
 Proton coupled oligopeptide transporters (POTs) are an integral plasma 
membrane protein family that transport a broad spectrum of di/tripeptides and a 
variety of peptidomimetic substrates across the membrane. To date, four 
mammalian members in the POT superfamily, PepT1 (SLC15A1), PepT2 
(SLC15A2), PhT1 (SLC15A4), and PhT2 (SLC15A3), have been identified and 
characterized functionally, each with both diverse and similar substrate 
specificities, capacities and affinities (Fei, Kanai et al. 1994; Brandsch 2009; 
Brandsch 2013; Smith, Clemencon et al. 2013). PepT1, the most widely studied 
transporter among the POT family, is considered to play a pivotal role in the oral 
absorption of small peptides and peptidomimetic drugs due to its dominant 
expression along the small intestine. Besides di/tripeptides, PepT1 can transport 
and influence the pharmacokinetics of a variety of therapeutic drugs with different 
structural and chemical characteristics, including some β-lactam antibiotics (e.g., 
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cefadroxil), angiotensin converting enzyme inhibitors (e.g., enalapril) and 
antiviral prodrugs (e.g., valacyclovir). Many studies have been conducted and 
focused on understanding the mechanism and contribution of PepT1 toward the 
absorption and disposition of these drugs. 
 Previous research suggested that transporter-mediated (e.g., PepT1, PAT1) 
active uptake may play an important role in facilitating 5-ALA intestinal 
absorption and its good oral bioavailability (Doring, Walter et al. 1998; Anderson, 
Jevons et al. 2010; Frolund, Marquez et al. 2010). However, the relative 
contribution of intestinal transporter PepT1 (Slc15a1) in this process is not clear, 
as compared to other potential intestinal transporters such as PAT1 (Slc36a1) and 
PhT1/2 (Slc15a4/ Slc15a3). The PepT1 knockout mouse generated in our 
laboratory provides us a powerful research tool to evaluate the relevance of PepT1 
in the intestinal effective permeability and absorption of model compounds and 
drugs (e.g., glycylsarcosine, cefadroxil, valacyclovir, fMet-Leu-Phe) (Hu, Smith 
et al. 2008; Jappar, Wu et al. 2010; Posada and Smith 2013; Wu and Smith 2013; 
Yang and Smith 2013). 
 Given this background information, the primary aim of the present study 
was to determine the quantitative contribution of PepT1 on the intestinal 
permeability of 5-ALA, via in situ single-pass perfusions, in wildtype and PepT1 
knockout mice. Specifically, the regional permeability, substrate specificity and 
concentration dependency of 5-ALA were studied in mice. The possible role of 
other potential transporters in the intestinal absorption of 5-ALA was also 
investigated.  
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MATERIALS AND METHODS 
Animals 
 All experiments performed on mice were carried out in accordance with 
the Guide for the Care and Use of Laboratory Animals as adopted by the U.S. 
National Institutes of Health. Gender-matched wildtype and PepT1 knockout mice 
(>99% C57BL/6 genetic background, 8-10 week old) were used in all 
experiments (Hu, Smith et al. 2008). The mice were kept under a 12-hour 
light/dark cycle and in an ambient temperature-controlled environment, fed with 
standard diet and water ad libitum (Unit for Laboratory Animal Medicine, 
University of Michigan, Ann Arbor, MI). 
Materials 
 [
14
C]5-ALA (55 mCi/mmol) and [
3
H]inulin (201 mCi/g)
 
were purchased 
from American Radiolabeled Chemicals (St. Louis, MO). All other reagents were 
obtained from Sigma-Aldrich (St. Louis, MO). 
Stability of 5-ALA in Intestinal Segments  
 In situ single-pass perfusions were performed in different intestinal 
segments, the outlet perfusate samples collected and subsequently analyzed by 
High Performance Liquid Chromatography (HPLC). The HPLC system consisted 
of a Waters 515 pump (Waters Inc., Milford, MA), a -RAM 5 radiochemical 
detector and Laura (Version 4.1.8) data acquisition software (LabLogic Systems, 
Brandon, FL). A reversed-phase 250 × 4.6 mm C18 column (Discovery, Supelco, 
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Bellefonte, PA) was used for chromatographic separation. The mobile phase 
consisted of 5% acetonitrile plus 0.1% TFA, pumped isocratically at 1.0 mL/min 
under ambient conditions. All perfusate samples were centrifuged at 10,000 × g 
for 10 minutes and 20 L aliquots of supernatant were injected manually into the 
HPLC. Under these conditions, the retention time of [
14
C]5-ALA was 4.1 minutes. 
In Situ Single-Pass Jejunal Perfusion Studies 
 Gender-matched wildtype and PepT1 knockout mice were fasted 
overnight (approximately 16 hours) with free access to water. Perfusion 
experiments were performed according to the methods described previously 
(Adachi, Suzuki et al. 2003; Jappar, Wu et al. 2010). Briefly, the mice were 
anesthetized with sodium pentobarbital (40-60 mg/kg i.p.) and placed on a heated 
pad to maintain normal body temperature after anesthesia. Prior to surgery, 
isopropyl alcohol was applied to wet and sterilize the abdominal area, and then 
the abdomen was opened through a 1.5-cm midline incision longitudinally to 
expose the small intestine. For jejunal perfusion, an 8 cm segment of proximal 
jejunum was isolated (i.e., ~2 cm distal to the ligament of Treitz) with incisions 
made at both proximal and distal ends. Glass cannulas (2 mm outer diameter) 
were inserted into both ends of the jejunum and secured in place with silk suture. 
Following cannulation, the isolated intestinal segment was rinsed with isotonic 
saline solution, and covered with saline-wetted gauze and parafilm to prevent 
dehydration. After the surgical procedure, the mice were transferred to a 
temperature-controlled chamber (31°C) to maintain the body temperature during 
the experiment. The inlet cannula was connected to a 30-mL syringe placed on a 
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perfusion pump (Model 22; Harvard Apparatus, South Natick, MA) and the outlet 
tubing was placed in a collection vial.  
 The perfusion buffer (pH 6.5), containing 135mM NaCl, 5mM KCl, 10 
mM MES, 0.01 % (w/v) [
3
H]inulin, and [
14
C]5-ALA, was perfused through the 
intestinal segment at rate of 0.1 ml/min for 90 min. The exiting perfusate was 
collected every 10 min for 90 min. A 100 l aliquot from each 10-min collection 
was added to a vial containing scintillation fluid (CytoScint®, MP Biomedicals, 
Solon, OH) and measured by a dual-channel liquid scintillation counter (Beckman 
LS 6000 SC, Beckman Coulter, Inc, Fullerton, CA). The permeability of 5-ALA 
uptake in jejunum was determined at steady-state, which was achieved after 30 
minutes of perfusion. Water flux was corrected by the non-permeable marker 
[
3
H]inulin. At the end of experiments, the length of intestinal segments was 
directly measured. 
 For concentration-dependent perfusion studies, the 5-ALA concentration 
in perfusate varied over a broad range (0.01 – 50 mM) to assess the saturable 
jejunal uptake kinetics of 5-ALA in wildtype mice.  
 To examine the specificity of PepT1-mediated uptake of 5-ALA, the 
jejunum of wildtype mice was co-perfused with 10 M 5-ALA and 25 mM of 
potential inhibitors such as GlySar, cefadroxil, tetraethylammonium (TEA), p-
aminohippurate (PAH), L-histidine, L-proline or -alanine.  
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In Situ Single-Pass Segment-Dependent Perfusions 
 To characterize the effective permeability of 5-ALA in different intestinal 
regions, four major intestinal segments including duodenum, jejunum, ileum, and 
colon were isolated and perfused simultaneously in wildtype and PepT1 knockout 
mice. In addition to the jejunal segment, a 2-cm segment of duodenum   (i.e. ~ 
0.25 cm distal to the pyloric sphincter), a 6-cm segment of ileum (i.e., ~ 1 cm 
proximal to the cecum), and a 3-cm segment of colon (i.e., ~ 0.5 cm distal to the 
cecum) were isolated and perfused as previously described. 
Data Analysis 
The effective permeability of 5-ALA was calculated at steady-state (after 
30 min perfusion) by using the following formula:(Johnson and Amidon 1988) 
RL
CCQ
P inouteff
2
)/ln(

                                    
(1) 
Where Peff is the effective permeability, Cout and Cin are the outlet (corrected for 
water flux) and inlet concentrations of 5-ALA in perfusate, Q is the perfusate flow 
rate, R is the radius of intestinal segment, and L is the length of intestinal segment. 
The steady-state flux (J) through the intestinal membrane was calculated as: 
                                                                                                        (2)           ineff CPJ 
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The steady-state flux (J) across the intestinal membrane was then used to 
determine the kinetic parameters (Vmax' and Km') when referenced to inlet drug 
concentrations (Cin) as shown in eq. 3. 
                                                                                                        (3) 
 
Vmax and Km were also determined after factoring out the resistance across the 
unstirred water layer and the steady-state flux (J) was referenced to intestinal wall 
concentrations (Cw) as shown in eq. 4 (Johnson and Amidon 1988; Sinko and 
Amidon 1988). 
 
                                                                                   (4)
 
The relationship between intestinal wall and inlet drug concentrations is shown in 
eq. 5, where Paq is the unstirred aqueous layer permeability. 
                                                                                                           (5) 
The Paq was calculated by:  
                                                                                                           (6) 
                                                                                                           (7) 
Where D is the aqueous diffusion coefficient (6.596*10
-4
 cm
2
/min), calculated 
according to the Hayduk-Laudie expression, Gz is the Graetz number (0.0829), 
and A is a unitless constant (1.332) estimated by A = 2.5Gz + 1.125. 
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Statistical Analysis 
Data were reported as mean ± S.E. Unpaired two-tailed student’s t tests 
were used to compare statistical differences between two groups. One-way 
ANOVA followed by Dunnett’s or Tukey’s post hoc test were performed to 
compare statistical differences between multiple groups (Prism version 5.0; 
GraphPad Software Inc., La Jolla, CA). The quality of the fitting of nonlinear 
regression was assessed by the coefficient of determination (r
2
), by the variation 
of the parameter estimates, and by visual inspection of the residuals. For all the 
statistical significance tests, a p-value ≤ 0.05 was considered significant. 
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RESULTS 
Stability of 5-ALA in Intestinal Segments  
Stability of 5-ALA was assessed during the in situ single-pass intestinal 
perfusion studies. As shown in Fig. 3.1, there is no metabolism or degradation of 
5-ALA in pre- and post-perfusion buffer (pH 6.5) for the small and large intestinal 
segments. Although 5-ALA is known to convert into its metabolite PpIX rapidly 
in the mitochondria under intracellular condition, our findings indicates 5-ALA is 
quite stable in the lumen of gastrointestinal tract during the perfusion procedure. 
This phenomenon is consistent and the same in the PepT1 knockout mice as well 
as wildtype mice (Fig. 3.2). These results suggest the 5-ALA effective 
permeability can be determined directly by loss of 5-ALA in perfusate and 
without concern on its stability during the following perfusion studies.  
Concentration-Dependent Perfusion Studies 
To evaluate whether the jejunal uptake kinetics of 5-ALA was saturable, 
in situ perfusion experiments were conducted over a wide range of 5-ALA 
concentrations in perfusate (0.01 – 50 mM) of wildtype mice. As depicted in 
Figure 3.3, the jejunal uptake of 5-ALA exhibited a saturable profile that was best 
described by Michaelis-Menten kinetics, where transport parameters were 
estimated as Vmax' = 2.30 ± 0.16 nmol/cm
2
/sec and Km' = 13.4 ± 2.44 mM when 
referenced to inlet perfusate concentrations (R
2
 = 0.937). When referenced to 
intestinal wall concentrations (Fig. 3.4), the intrinsic absorption parameters were 
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estimated as Vmax = 1.89 ± 0.12 nmol/cm
2
/sec and Km = 3.74 ± 0.95 mM (R
2
 = 
0.857). 
Substrate Specificity Studies 
To probe the specificity of the PepT1-mediated jejunal transport of 5-ALA, 
the effective permeability of 10 μM 5-ALA was evaluated by co-perfusion with a 
variety of potential inhibitors (25 mM). As shown in Figure 3.5, 5-ALA jejunal 
permeability was substantially reduced in the presence of the typical PepT1 
substrates GlySar (residual of 31%) or cefadroxil (residual of 16%). In contrast, 
the 5-ALA jejunal permeability was not altered when co-perfused with L-histidine 
(i.e., an amino acid substrate of PhT1/2), L-proline (i.e., an amino acid substrate 
of PAT1), β-alanine (i.e., an amino acid substrate of PAT1), TEA (an organic 
cation substrate of OCTs) or PAH (an organic anion substrate of OATs). These 
results demonstrated that the jejunal permeability of 5-ALA was primarily 
mediated by PEPT1. The contribution of other transporters, including PAT1, in 
mediating the intestinal permeability of 5-ALA is unlikely and minor at best.  
Segment-Dependent Perfusion Studies  
To investigate whether the 5-ALA permeability would be affected by the 
differential expression of PepT1 along the small and large intestines, the effective 
permeability of 10 μM 5-ALA was measured in four intestinal segments and the 
results compared between genotypes. As demonstrated in Figure 3.6, the mean 
effective permeability (Peff) of 5-ALA in wildtype mice was determined as 
1.65×10
-4
 cm/s in duodenum, 1.91×10
-4
 cm/s in jejunum, 1.20×10
-4
 cm/s in ileum 
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and 0.14×10
-4
 cm/s in colon. The Peff of 5-ALA in the duodenum, jejunum, and 
ileum of PepT1 knockout mice was approximately 10% of that in wildtype 
animals. Colonic Peff values were very small and not different between the two 
genotypes. Moreover, no statistical differences in the Peff of 5-ALA were 
observed between any of the intestinal segments in PepT1 knockout mice.  
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DISCUSSION 
Numerous studies have focused on investigating the function and 
relevance of PepT1 in the intestinal uptake of a variety of peptide-like drugs 
(Daniel and Kottra 2004; Brandsch 2009; Brandsch 2013; Smith, Clemencon et al. 
2013). The photodynamic therapy agent 5-ALA has been shown to be a substrate 
of PepT1 in hPepT1-expressing yeast cells (Doring, Walter et al. 1998; Rodriguez, 
Batlle et al. 2006), human bile duct tumor cells (Neumann and Brandsch 2003; 
Chung, Kim et al. 2013), human gastric cancer cells (Hagiya, Endo et al. 2012), 
hPepT1-expressing Xenopus oocytes (Anderson, Jevons et al. 2010), stably 
transfected hPepT1-expressing Madin-Darby canine kidney (MDCK) cells 
(Frolund, Marquez et al. 2010) and hPepT1-expressing Caco-2 cells (Anderson, 
Jevons et al. 2010; Frolund, Marquez et al. 2010). However, these in vitro studies 
were inherently deficient in probing the precise contribution of PepT1 on 5-ALA 
intestinal absorption because they lacked an intact blood supply and, thus, a 
normal physiological environment. The recent development of genetically-
modified mice has provided us a unique animal model to tackle this problem and 
characterize the functional activity of PepT1 under physiological conditions (Hu, 
Smith et al. 2008). 
The present study has revealed several novel findings in determining the 
predominant role of transporter PepT1 on the intestinal absorption of 5-ALA via 
in situ single-pass perfusions in wildtype and PepT1 knockout mice. In particular, 
we found that (1) 5-ALA exhibited stability in the lumen of the gastrointestinal 
tract under perfusion conditions; (2) jejunal uptake of 5-ALA was carrier-
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mediated and saturable with an intrinsic Km value of 3.7 mM; (3) intestinal 
transport of 5-ALA was dependent on PepT1 while the potential contribution of 
other transporters (e.g., PAT1) was extremely low; (4) the permeability of 5-ALA 
in small intestine was approximately 10-fold higher in wildtype as compared to 
PepT1 knockout mice; (5) colonic permeability of 5-ALA was only about 10% of 
that observed in small intestine of wildtype animals and showed no difference 
between two genotypes.   
The high capacity and low affinity nature of transporter PepT1, relative to 
PepT2, has been characterized in many studies (Brandsch, Knutter et al. 2008; 
Rubio-Aliaga and Daniel 2008; Smith, Clemencon et al. 2013). The apparent 
Michaelis–Menten affinity constant (Km) for a typical substrate of PepT1 was 
usually reported in the mM range (i.e., 0.1-10 mM), depending upon the substrate 
specificity, species difference and type of experimental system. As shown in the 
literature, Km values of 5-ALA were estimated under different experimental 
systems and reported as 0.4 mM in hPepT1-expressing yeast cells (Doring, Walter 
et al. 1998), 6.4 mM in transfected hPepT1-expressing MDCK cells (Frolund, 
Marquez et al. 2010) and 1.6 mM in hPepT1-expressing Xenopus oocytes 
(Anderson, Jevons et al. 2010). In this study, the transport properties of 5-ALA 
were evaluated with escalating concentrations (i.e., 0.01-50 mM) in jejunum of 
wildtype mice. The kinetic profile was best fitted by a Michaelis-Menten equation 
with an estimated intrinsic Km value equal to 3.74 mM when referenced to 
intestinal wall concentrations of 5-ALA. Therefore, the Km value obtained in our 
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studies was comparable with literature values reported previously and highly 
consistent with the low-affinity feature of PepT1-mediated transport. 
In wildtype mice, the effective permeability values of 5-ALA in 
duodenum, jejunum and ileum were 1.65 ± 0.07×10
-4
 cm/s, 1.91 ± 0.13×10
-4
 cm/s 
and 1.20 ± 0.05×10
-4
 cm/s, respectively, while the colonic Peff value was only 
0.14 ± 0.05×10
-4
 cm/s, a value significantly lower than those observed in the 
small intestinal segments. These results which reflect PepT1 functional activity, 
were very similar to the PepT1 protein expression pattern along the small and 
large intestines as previous reported (i.e., abundant in small intestine but 
negligible in colon) (Jappar, Wu et al. 2010). In contrast, the residual Peff of 5-
ALA in the duodenum, jejunum, and ileum of PepT1 knockout mice was only 
about 10% of that in wildtype mice and similar to that of colon Peff, indicating that 
PepT1 was responsible for approximately 90% of 5-ALA uptake in mouse small 
intestine. This conclusion was consistent with previous results for other PepT1 
substrates (e.g., GlySar, valacyclovir, cefadroxil) in the same experimental 
platform (Jappar, Wu et al. 2010; Posada and Smith 2013; Yang and Smith 2013). 
The potential contribution of other transporters in the jejunal uptake of 5-
ALA was examined in the wildtype mice through inhibition studies. Specifically, 
excessive concentrations of known PepT1 substrates or non-substrates (25 mM) 
were added to the buffer during the in situ perfusion studies. Not surprisingly, two 
typical PepT1 substrates, the di-peptide GlySar and the aminocephalosporin drug 
cefadroxil, significantly reduced the intestinal permeability of 5-ALA. In contrast, 
other potential inhibitors including the amino acids L-histidine, L-proline, β-
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alanine, the organic base TEA and the organic acid PAH, all failed to exhibit any 
inhibition activity when perfused concomitantly with 5-ALA. These results 
supported the dominant and probably exclusive role of PepT1 in the small 
intestinal uptake of 5-ALA. The residual permeability of 5-ALA in the small and 
large intestines after PEPT1 gene ablation would also argue against a significant 
role of other transporters in the uptake of 5-ALA. It is worth noting that this 
conclusion is contradictory to other studies regarding the role of the amino acid 
transporter PAT1 in transporting 5-ALA. In this regard, 5-ALA was reported to 
be a substrate of the transporter PAT1 as tested in Caco-2 cells, hPAT1-
expressing COS-7 cells and hPAT1-expressing oocytes (Anderson, Jevons et al. 
2010; Frolund, Marquez et al. 2010). Although several amino acid transporters for 
-amino acids exist, PAT1 (SLC36A1) is the only proton-coupled amino acid 
transporter involved in the intestinal uptake of small zwitterionic -amino acids 
such as proline, glycine and alanine (Thwaites, McEwan et al. 1995; Chen, Fei et 
al. 2003). Based on their in vitro uptake experiments, these authors argued that 5-
ALA showed substrate overlap between PepT1 and PAT1 in mediating 5-ALA 
uptake at the intestinal brush border membrane. However, our inhibition studies 
using the -amino acids L-proline and β-alanine clearly do not support this 
contention. In addition, the intestinal expression of PAT1 transcripts was 
substantially lower as compared to PEPT1 in wildtype mice (unpublished data in 
Smith group). Collectively, our in situ findings demonstrated that in mice the 
contribution of PAT1 is marginal at best in mediating 5-ALA intestinal uptake. 
72 
 
In conclusion, our in situ single-pass perfusion results in wildtype and 
PepT1 knockout mice provided strong evidence in defining the significant role of 
PepT1 in the intestinal permeability of 5-ALA. Moreover, these findings provided 
solid mechanistic basis for enhancing 5-ALA oral absorption via a PepT1 
targeting strategy. 
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FIGURES 
(A)                                                            (B) 
 
(C)                                                             (D) 
 
(E)                                                              (F) 
 
 
Figure 3.1 HPLC chromatogram of (A) blank perfusion buffer (B) 5-ALA in 
perfusate before and after perfusion from (C) duodenum (D) jejunum (E) ileum 
and (F) colon segments in wildtype mouse. The chromatographic peak at 4.1 min 
represents 5-ALA. 
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(A)                                                            (B) 
 
(C)                                                             (D) 
 
 
 
 
Figure 3.2 HPLC chromatogram of 5-ALA in perfusate after perfusion from (A) 
duodenum (B) jejunum (C) ileum and (D) colon segments in PepT1 knockout 
mouse. The chromatographic peak at 4.1 min represents 5-ALA. 
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Figure 3.3 Concentration dependency of 5-ALA flux in the jejunum of wildtype 
mice (mean ± SE, n=4). Cin was referenced to the inlet concentration of 5-ALA. 
  
inm
in
CK
CV
J



 '
 'max
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Cin (mM)
5
-A
L
A
 F
lu
x
 (
n
m
o
l/
c
m
2
/s
e
c
)
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Concentration dependency of 5-ALA flux in the jejunum of wildtype 
mice (mean ±  SE, n=4). Cw was referenced to the estimated intestinal wall 
concentration of 5-ALA. 
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Figure 3.5 Effect of potential inhibitors (25 mM) on the effective permeability of 
10 μM 5-ALA during jejunal perfusion in wildtype mice. Data are presented as 
mean ± SE (n=4). Statistical analyses were performed by one-way ANOVA and 
Dunnett’s test. ***p < 0.001 as compared to control.   
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Figure 3.6 Effective permeability of 10 μM 5-ALA in the duodenum, jejunum, 
ileum, and colon of wildtype and PEPT1 knockout (KO) mice. Data are presented 
as mean ± SE (n=4). Groups with different letters are statistically different as 
determined by one-way ANOVA and Tukey’s test. 
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CHAPTER 4                                                                                                    
ROLE OF PEPT1 ON THE IN VIVO PHARMACOKINETICS OF 5-
AMINOLEVULINIC ACID IN WILD-TYPE AND PEPT1 KNOCKOUT 
MICE 
ABSTRACT   
PURPOSE: The aim of this study was to determine the contribution of 
oligopeptide transporter PepT1 in the absorption and disposition of the 
photodynamic therapy agent 5-aminolevulinic acid (5-ALA) via in vivo 
pharmacokinetic studies in wildtype and PepT1 knockout mice. 
METHODS: Radiolabeled [
14
C] 5-ALA was given to wildtype and PepT1 
knockout mice via oral gavage (0.2 and 2 mol/g body weight) or tail vein 
injection (0.01 mol/g body weight). Serial blood samples were collected over 
180 min and plasma concentrations of 5-ALA were measured using a dual-
channel liquid scintillation counter. Tissue distribution studies were also 
performed in wildtype and PepT1 knockout mice after oral administration of 0.2 
mol/g 5-ALA. The pharmacokinetic data was analyzed by a non-compartmental 
approach using Phoenix WinNonlin (version 1.3, Certara, St. Louis, MO). 
RESULTS: Following oral administration of 5-ALA for both oral doses, the Cmax 
and AUC0-180 of 5-ALA were substantially decreased approximately 2-fold in 
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PepT1 knockout mice, as compared to wildtype mice. However, the Cmax and 
AUC0-180 values were dose proportional for the two genotypes. After intravenous 
dosing, the pharmacokinetic profiles of 5-ALA were virtually superimposable 
between wildtype and PepT1 knockout mice. Also, tissue samples after oral 
dosing were measured and showed minor significant differences between the two 
genotypes. 
CONCLUSION: These findings demonstrate that PepT1 plays an important role 
in facilitating the intestinal absorption of 5-ALA. Moreover, 5-ALA oral kinetics 
exhibits an “apparent linearity” over the dose range studied. The tissue 
distribution study results combined with the intravenous pharmacokinetic study of 
5-ALA suggest that PepT1 deficiency does not affect the in vivo disposition of 
this substrate. 
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INTRODUCTION 
Proton coupled oligopeptide transporters (POTs) are an integral plasma 
membrane protein family that transport a broad spectrum of di-/tri-peptides and a 
variety of peptidomimetic substrates across biological membranes. To date, four 
mammalian members in the POT superfamily, PepT1 (SLC15A1), PepT2 
(SLC15A2), PhT1 (SLC15A4), and PhT2 (SLC15A3), have been identified and 
characterized functionally, each with diverse yet some overlapping substrate 
specificities, capacities and affinities (Fei, Kanai et al. 1994; Brandsch 2009; 
Brandsch 2013; Smith, Clemencon et al. 2013). All of these membrane proteins 
transport di- and tri-peptides in the body that are driven by an inwardly directed 
proton gradient and negative membrane potential. Whereas PepT1 and PepT2 can 
transport di-/tri-peptides, PhT1 and PhT2 can also transport the amino acid L-
histidine. PepT1 is the most widely studied and best characterized transporter 
among the POT family due to its physiological and pharmacological importance 
(Daniel and Kottra 2004; Rubio-Aliaga and Daniel 2008; Brandsch 2013; Smith, 
Clemencon et al. 2013). Compared to PepT2, PepT1 is considered a high-capacity 
low-affinity influx transporter with primary expression on the brush border 
membrane of epithelial cells in the small intestine. PepT1 is believed to play an 
essential physiological role in protein assimilation since approximately 80% of 
digested proteins are absorbed in the form of di-/tri-peptides that can enter the 
epithelial cells via PepT1-mediated active transport (Daniel 2004). Besides 
di/tripeptides, PepT1 can transport and influence the pharmacokinetics of a 
variety of therapeutic drugs with different structural and chemical characteristics, 
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including some β-lactam antibiotics (e.g., cefadroxil), angiotensin converting 
enzyme inhibitors (e.g., enalapril) and antiviral prodrugs (e.g., valacyclovir). 
Many studies have focused on understanding the mechanism and relative 
contribution of PepT1 towards the absorption and disposition of these drugs. 
5-Aminolevulinic acid (5-ALA), a naturally occurring intermediate in the 
heme biosynthesis pathway, has been widely used in photodynamic therapy and 
fluorescence detection for the last twenty years (Peng, Berg et al. 1997; Peng, 
Warloe et al. 1997; Kelty, Brown et al. 2002; Krammer and Plaetzer 2008). 
Currently, 5-ALA and its esters have been approved by the FDA as a promising 
treatment of several malignant and premalignant conditions such as actinic 
keratosis, basal cell carcinoma, Bowen’s disease, bladder cancer and others. In 
Europe, 5-ALA has been approved for intraoperative photodynamic diagnosis of 
residual malignant glioma while the methyl-ester and hexyl-ester derivatives of 5-
ALA have been approved for the treatment of basal cell carcinoma and actinic 
keratosis, and the diagnostic application of bladder cancer, respectively (Dolmans, 
Fukumura et al. 2003; Fotinos, Campo et al. 2006; Krammer and Plaetzer 2008; 
Nokes, Apel et al. 2013).   
Oral dosing is an administration route that is commonly used in the 
clinical application of 5-ALA. In practice, a high accumulation after of 5-ALA 
has been reported in normal enterocytes after oral administration (Loh, 
MacRobert et al. 1993; Regula, MacRobert et al. 1995). In addition, good oral 
bioavailability of 5-ALA was observed in several experimental and clinical 
studies (van den Boogert, van Hillegersberg et al. 1998; Dalton, Meyer et al. 1999; 
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Dalton, Yates et al. 2002) despite the fact that 5-ALA is a hydrophilic and polar 
molecule. Previous studies suggested that PepT1 may play an important role in 
facilitating 5-ALA intestinal absorption and its good oral bioavailability (Doring, 
Walter et al. 1998; Anderson, Jevons et al. 2010; Frolund, Marquez et al. 2010). 
Moreover, based on in vitro uptake experiments performed in Caco-2 cells, 
hPAT1-expressing COS-7 cells and hPAT1-expressing oocytes (Anderson, 
Jevons et al. 2010; Frolund, Marquez et al. 2010), 5-ALA was also indicated to be 
a substrate of the amino acid transporter PAT1. It was speculated that both PepT1 
and PAT1 are involved in mediating 5-ALA uptake at the intestinal brush border 
membrane in vivo. 
Collectively, the transport mechanism of 5-ALA from the gastrointestinal 
tract lumen into the systemic circulation system is still poorly understood and the 
relative contribution of intestinal transporter PepT1 in the in vivo oral absorption 
of 5-ALA is unclear. To better understand the process of 5-ALA intestinal 
absorption and determine the contribution of transporter PepT1 quantitatively in 
this process, comparative pharmacokinetic and tissue distribution studies of 5-
ALA were performed in wildtype and PepT1 knockout mice.  
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MATERIALS AND METHODS 
Animals 
All experiments performed on mice were carried out in accordance with 
the Guide for the Care and Use of Laboratory Animals as adopted by the U.S. 
National Institutes of Health. Gender-matched wildtype and PepT1 knockout mice 
(>99% C57BL/6 genetic background, 8-10 week old) were used in all 
experiments (Hu, Smith et al. 2008). The mice were kept under a 12-hour 
light/dark cycle and in an ambient temperature-controlled environment, fed with 
standard diet and water ad libitum (Unit for Laboratory Animal Medicine, 
University of Michigan, Ann Arbor, MI).  
 
Materials 
[
14
C]5-ALA (55 mCi/mmol) and [
3
H]dextran (MW 70000, 100 mCi/g)
 
were purchased from American Radiolabeled Chemicals (St. Louis, MO). 
Hyamine hydroxide was obtained from ICN Pharmaceuticals (Costa Mesa, CA). 
Unlabeled 5-ALA hydrochloride and other reagents were obtained from Sigma-
Aldrich (St. Louis, MO). 
 
Pharmacokinetic study of 5-ALA after oral administration 
An oral pharmacokinetic (PK) study was performed on wildtype and 
PepT1 knockout mice according to the procedure described below. Briefly, 
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gender-matched wildtype and PepT1 knockout mice were fasted overnight prior 
to each experiment. Radiolabeled [
14
C]5-ALA and cold 5-ALA were dissolved in 
normal saline (0.04 Ci/L) to prepare the drug solution. 5-ALA drug solution 
(10 L/g, 0.4 Ci per mouse) was administered orally by gavage (20-gauge 
needle) at single doses of 0.2 or 2 mol/g body weight. Serial blood samples were 
collected (~20 l) via tail nicks in 0.2 ml microcentrifuge tubes containing 7.5% 
potassium EDTA at 5, 10, 20, 30, 45, 60, 90, 120, 150 and 180 min after the 
initial oral dose. Plasma was obtained after centrifuging at 3000 g for 3 min and a 
10-L aliquot was transferred to a glass scintillation vial. CytoScint (MP 
Biomedicals, Solon, OH) scintillation fluid (6 ml) was added to each sample and 
radioactivity of the plasma sample was measured by a dual-channel liquid 
scintillation counter (Beckman LS 6000 SC; Beckman Coulter Inc., Fullerton, CA, 
USA). At 45 min after oral dosing, mice were given intraperitoneal injections of 
0.3 ml warm saline to prevent dehydration. 
 
Tissue distribution of 5-ALA after oral administration 
Tissue distribution studies were performed in wildtype and PepT1 
knockout mice after the 0.2 mol/g oral administration of [14C]5-ALA. Tissue 
samples were collected at the last time point (i.e., 180 min) of the oral PK study. 
To determine the tissue vascular space, 100 L of [3H]dextran 70,000 (0.2 
Ci/mouse) was administered via a tail vein injection 5 minutes before harvesting 
the tissues. Several tissues including the eye, spleen, duodenum, jejunum, ileum, 
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colon, stomach, kidney, liver, lung, heart and skeletal muscle were harvested, 
blotted dry, weighed, and then solubilized in 0.33 ml of 1 M hyamine hydroxide 
overnight at 37°C. Whole blood samples (10 L) were also collected at the same 
time. After incubation with hyamine hydroxide, a 40 l aliquot of hydrogen 
peroxide (30% w/w) was added to each sample for decolorization. A 6 mL aliquot 
of CytoScint scintillation fluid (MP Biomedicals, Solon, OH) was then added to 
the tissue samples, and radioactivity of the samples was measured by a dual-
channel liquid scintillation counter.   
The corrected tissue concentrations of 5-ALA were calculated via the 
following equation (Ocheltree, Shen et al. 2005; Shen, Ocheltree et al. 2007):  
Ctiss.corr = Ctiss – V × Cb 
where Ctiss.corr and Ctiss are the corrected and uncorrected tissue concentration of 5-
ALA (nmol/g), V is the blood vascular space as determined by dextran in the 
tissue (ml/g), and Cb is the 5-ALA blood concentration (nmol/mL). 
 
Pharmacokinetics of 5-ALA after intravenous administration 
An intravenous PK study was performed on wildtype and PepT1 knockout 
mice as described previously (Yang, Hu et al. 2013) and below. Briefly, 
radiolabeled [
14
C]5-ALA and cold 5-ALA were dissolved in normal saline (0.025 
Ci/L, 2 nmol/L) to prepare the drug solution. Following sodium pentobarbital 
anesthesia (~40-60 mg/kg i.p.), wildtype and PepT1 knockout mice received 
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[
14
C]5-ALA (10 nmol/g body weight) through a tail vein injection. Serial blood 
samples were collected (~20 L/sample) via tail nicks in 0.2 mL microcentrifuge 
tubes containing 7.5% potassium EDTA at 0.25, 1, 2, 5, 10, 15, 20, 30, 45, and 60 
min after the intravenous bolus dose. For each sample, a 10 uL aliquot of plasma 
was obtained after centrifugation at 3000 g for 3 min and then transferred to a 
glass scintillation vial. A 6 mL aliquot of scintillation fluid (CytoScint®, MP 
Biomedicals, Solon, OH) was added to each sample and radioactivity was 
measured by a dual-channel liquid scintillation counter (Beckman LS 6000 SC; 
Beckman Coulter Inc., Fullerton, CA, USA). 
 
Data analysis 
The pharmacokinetics of 5-ALA plasma concentration versus time profiles, 
after oral and intravenous administration, was performed by non-compartmental 
and compartmental approaches (Phoenix WinNonlin version 1.3; Certara, St. 
Louis, MO). For compartmental analysis, 5-ALA plasma concentration-time 
profiles were best fitted to a two-compartment disposition model with or without 
first-order absorption. Model selection was based on visual inspection of the 
individual fits and diagnostic plots, the Akaike Information Criterion (AIC) and 
coefficient of determination (r
2
). 
Two-compartment models for disposition after oral and intravenous 
dosing are shown below as: 
𝐶(𝑡) = 𝐴 ∙ 𝑒−𝛼𝑡 + 𝐵 ∙ 𝑒−𝛽𝑡  + 𝐶 ∙ 𝑒−𝐾𝑎𝑡        (oral) 
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𝐶(𝑡) = 𝐴 ∙ 𝑒−𝛼𝑡 + 𝐵 ∙ 𝑒−𝛽𝑡       (intravenous)             
Data are reported as mean ± standard error (S.E.). An unpaired two-tail 
Student’s t test was used to compare statistical differences between the two 
genotypes of mice (Prism version 5.0; GraphPad Software Inc., La Jolla, CA). P-
values < 0.05 were considered statistically significant. 
95 
 
RESULTS 
Pharmacokinetic studies following oral 5-ALA  
The average plasma concentration-time curves following 5-ALA oral 
administration of 0.2 mol/g and 2 mol/g doses in both wildtype and PepT1 
knockout mice were depicted in Figure 4.1 and Figure 4.2, respectively. As shown 
in both linear and logarithmic scales, the systemic exposure of 5-ALA at both oral 
doses was significantly different wildtype and knockout mice. Generally, in 
wildtype mice, the 5-ALA plasma concentrations increased rapidly and reached 
maximum values (Cmax) at around 10 minutes. The plasma concentrations then 
decreased quickly until around 60 minutes, followed by a slower terminal phase. 
In PepT1 knockout mice, the maximum plasma concentrations (Cmax) of 5-ALA 
were substantially lower than wildtype mice. However, no significant differences 
in the time to reach maximum concentration (Tmax) were observed between the 
two genotypes.   
Pharmacokinetic parameters were determined for the 0.2 and 2 mol/g 
oral doses by non-compartmental analysis (Phoenix WinNonlin) and summarized 
in Table 4.1 and 4.3, respectively. The systemic exposure AUC0-180  values were 
reduced by approximately 55% in PepT1 knockout mice compared with wildtype 
animals (p<0.01), suggesting reduced extent of 5-ALA oral absorption and 
systemic exposure due to PEPT1 ablation. The Tmax values, an indicator of oral 
absorption rate, were not statistically different between wildtype and PepT1 
knockout mice. 
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Dose-proportionality of 5-ALA Cmax and AUC0-180 following oral 5-ALA 
in both genotypes was evaluated over the two oral doses of 0.2 and 2 mol/g. The 
dose-normalized values of Cmax and AUC0-180 were close and showed no statistical 
difference, indicating an “apparent linearity” over the dose range in both 
genotypes.   
5-ALA tissue distribution after oral administration  
Given the broad expression profiles of 5-ALA across different tissues, 
investigating the role of PepT1 on the in vivo distribution of 5-ALA was of 
interest.  Tissue distribution studies were performed 180 minutes after oral 
administration of 0.2 mol/g 5-ALA. As shown in Figure 4.3, there were no 
statistically significant differences of 5-ALA tissue concentrations in almost all 
the tissues sampled between the two genotypes. However, for heart and ileum, 
significantly higher tissue concentrations of 5-ALA were found in wildtype mice 
than that in PepT1 knockout mice. No significant differences of 5-ALA 
concentrations were observed in other non-gastrointestinal (GI) tissues and GI 
segments including stomach, duodenum, jejunum and colon between the two 
genotypes. In order to rule out the differences in tissue concentrations caused by 
the differences in systemic exposure, 5-ALA tissue concentrations were 
normalized by its blood concentration. The results in Figure 4.4 demonstrated a 
similar pattern as observed in Figure 4.3. Only 5-ALA in wildtype ileum was 
higher than that in Pept1 knockout mice. These results indicated that PepT1 does 
not play an important role in affecting the in vivo disposition of 5-ALA. 
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Pharmacokinetic studies following intravenous 5-ALA 
In addition to tissue distribution studies after oral dosing, the systemic 
exposure of 5-ALA was examined in wildtype and PepT1 knockout mice after 
0.01 mol/g intravenous bolus administration. As depicted in the Figure 4.5, 
mean 5-ALA plasma concentration versus time curves were nearly 
superimposable between the two genotypes. Pharmacokinetic parameters derived 
from non-compartmental and compartmental analyses were summarized in Table 4.5 
and Table 4.6, without showing any statistical difference between the two 
genotypes. These results supported the contention that the role of PepT1 on the in 
vivo disposition of 5-ALA in mice was minimal at best. 
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DISCUSSION 
In vitro uptake studies have demonstrated the PepT1-mediated transport of 
5-ALA in various cell systems expressing PepT1 (Doring, Walter et al. 1998; 
Neumann and Brandsch 2003; Anderson, Jevons et al. 2010; Frolund, Marquez et 
al. 2010; Hagiya, Endo et al. 2012; Chung, Kim et al. 2013; Hagiya, Fukuhara et 
al. 2013).  By performing in situ intestinal perfusion studies of 5-ALA in wildtype 
and PepT1 knockout mice, we have shown that PepT1-mediated active transport 
is the main route of 5-ALA uptake in mouse small intestine, accounting for 
approximately 90% of 5-ALA permeability in various small intestinal segments of 
wildtype mice. In contrast, the potential contribution of other transporters (e.g., 
PAT1) in the intestinal absorption of 5-ALA was extremely low. These findings 
from intestinal permeability assessments of 5-ALA provided the first quantitative 
measure for the relative importance of PepT1 in intestinal absorption of 5-ALA. 
The current pharmacokinetic and tissue distribution studies, aimed at examining 
the in vivo contribution of PepT1 on 5-ALA pharmacokinetics at clinically 
relevant doses, were performed in wildtype and PepT1 knockout mice after oral 
and intravenous dosing.  
New findings obtained from this study included the following: 1) the 
systemic exposure of 5-ALA was reduced by 55% after oral administration of 
drug in PepT1 knockout versus wildtype mice; 2) PepT1 deletion reduced the 
Cmax of  5-ALA to ~46-63% of that in wildtype mice; 3) there was an “apparent 
dose linearity” in the Cmax and AUC0-180  of 5-ALA for both genotypes over the 
two oral doses 0.2 and 2 mol/g; 4) the systemic disposition of 5-ALA was 
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unchanged in both genotypes after intravenous administration; and 5) PepT1 had, 
at best, a minor effect on the peripheral tissue distribution of 5-ALA after oral 
dosing. 
After oral administration of 5-ALA, significant differences were observed 
in 5-ALA plasma concentration versus time profiles between two genotypes. As 
shown in Figure 4.1 and 4.2, for each dose, 5-ALA plasma levels in wildtype 
were always significantly higher than that in PepT1 knockout mice at the same 
time point after oral dosing, indicating a different absorption profile between two 
genotypes. The non-compartmental analysis for oral pharmacokinetic study 
revealed PepT1 deficiency leads to 2-fold differences in AUC and Cmax, 
corroborating the quantitative importance of PepT1 in the intestinal absorption of 
5-ALA. These results confirmed our previous in situ perfusion findings that 
PepT1 plays a pivotal role in the intestinal uptake of 5-ALA, accounting for 90% 
of its intestinal permeability. However, the magnitude of the contribution of 
PepT1 was found to be less pronounced in vivo than in situ, with only 2-fold as 
opposed to 10-fold differences between the two genotypes.  A similar discrepancy 
was observed for other PepT1 substrates (e.g., GlySar, valacyclovir) in the same 
experimental platform (Jappar, Hu et al. 2011; Yang, Hu et al. 2013). One 
possible explanation for the discrepancy is that other passive transport 
mechanisms (e.g., passive perfusion, paracellular transport) may play a bigger 
role in the in vivo absorption of 5-ALA than previously believed, given that the 
molecular weight of 5-ALA is only 131. In addition, the in vivo transit of 5-ALA 
from proximal small intestine to distal large intestine may affect the overall extent 
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of intestinal absorption of 5-ALA, which reduces the gap between in situ and in 
vivo results. For example, 5-ALA might undergo more absorption in the distal 
regions of small intestine and the entire large intestine in PepT1 knockout mice 
given the long residence times in these regions and the greater residual 
concentrations of drug and, therefore, driving force for absorption.  
Another interesting finding is that the time to reach maximum plasma 
concentration (Tmax) is around 10 min after oral dosing with no significant 
difference between the two genotypes. This result indicates that the in vivo 
intestinal absorption of 5-ALA in mice is a rapid process and a large portion of 
the 5-ALA dose is absorbed in the upper GI tract. Compared to the Tmax value of 
other PEPT1 substrates such as cefadroxil and valacyclovir (i.e., ~20 min in 
wildtype mice), the Tmax of 5-ALA is somewhat smaller. Although speculative, 
the smaller molecular weight, and presumably greater paracellular absorption, 
might explain the similar Tmax values in both wildtype and PepT1 knockout mice. 
To further assess the rate and extent of 5-ALA absorption in wildtype and PepT1 
knockout mice, compartmental model analyses were performed (Table 4.2 and 
4.4). Consistent with the noncompartmental analyses, no differences were 
observed between the genotypes in both Tmax as well as the absorption rate 
constant (Ka).   
Dose proportionality of AUC0-180 and Cmax of 5-ALA were observed in both 
genotypes of mice at oral doses of 0.2 and 2 mol/g. These two oral doses were 
selected by allometric scaling of clinical doses based on body surface area. The 
dose-normalized values of Cmax and AUC0-180 were close and showed no statistical 
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differences. Although it is possible that changes in bioavailability (F) and 
systemic clearance (CL), if these changes were of the same magnitude and 
direction, can result in no change in the dose-normalized value of AUC 
(AUC/Dose=F/CL), this possibility is highly unlikely since the Tmax  and terminal 
half-life values were not different between the lower and higher doses for each 
genotype.   
Tissue distribution studies, performed 180 minutes after oral 
administration of 0.2 mol/g 5-ALA, showed no statistical differences in the 
peripheral tissue concentration of 5-ALA except for heart, which was not 
statistically different when normalized for blood concentrations between the two 
genotypes (Figure 4.3 and 4.4). These findings, combined with previous tissue 
distribution studies of PepT1 substrates (e.g., GlySar, cefadroxil, valacyclovir), 
demonstrated that PepT1 expression in the peripheral tissues had a minor to no 
effect on the extent of drug distribution in the body (Jappar, Hu et al. 2011; 
Posada and Smith 2013; Yang, Hu et al. 2013). Our intravenous pharmacokinetic 
study of 5-ALA supported this conclusion since the drug disposition profiles were 
virtually identical between genotypes (Figure 4.5). Again, this result was 
consistent with other pharmacokinetic studies from our laboratory for GlySar, 
cefadroxil, and valacyclovir in wildtype and PepT1 knockout mice. 
In conclusion, results from this study characterize, for the first time, the in 
vivo pharmacokinetics of the photodynamic therapy agent 5-ALA in wildtype and 
PepT1 knockout mice after two clinically relevant oral doses. In particular, PepT1 
ablation significantly reduced the extent of intestinal absorption of 5-ALA in 
102 
 
PepT1 knockout mice while PepT1 only marginally affected, at best, the in vivo 
tissue distribution and disposition of 5-ALA. 
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Figure 4.1 Plasma concentration-time curves of 5-ALA in wildtype and PepT1 
knockout (KO) mice after oral administration of 0.2 mol/g [14C]5-ALA. The y-
axis is displayed as a linear scale (A) or a logarithmic scale (B). Data are 
presented as mean ± SE (n=4-5). 
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Figure 4.2 Plasma concentration-time curves of 5-ALA in wildtype and PepT1 
knockout (KO) mice after oral administration of 2 mol/g [14C]5-ALA. The y-
axis is displayed as a linear scale (A) or a logarithmic scale (B). Data are 
presented as mean ± SE (n=4). 
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Figure 4.3 Tissue concentrations of 5-ALA 180 min after oral administration of 
0.2 mol/g [14C] 5-ALA in wildtype and PepT1 knockout (KO) mice: (A) non-
gastrointestinal tissues; (B) gastrointestinal segments. Data are expressed as mean 
± SE (n= 4-5). ** p<0.01, compared with wildtype mice. 
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Figure 4.4 Tissue-to-blood concentration ratios of 5-ALA 180 min after oral 
administration of 0.2 mol/g [14C] 5-ALA in wildtype and PepT1 knockout (KO) 
mice: (A) non-gastrointestinal tissues; (B) gastrointestinal segments. Data are 
expressed as mean ± SE (n= 4-5). ** p<0.01, compared with wildtype mice. 
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Figure 4.5 Plasma concentration-time curves of 5-ALA in wildtype and PepT1 
knockout (KO) mice after intravenous dosing of 0.01 mol/g [14C] 5-ALA. The y-
axis is displayed as a linear scale (A) or a logarithmic scale (B). Data are 
presented as mean ± SE (n=7). 
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Table 4.1 Noncompartmental analysis of 5-ALA after oral administration of 0.2 
mol/g [14C] 5-ALA in wildtype (WT) and PepT1 knockout (KO) mice 
 
Parameter (unit) Wildtype PepT1 KO Ratio (KO/WT) 
Cmax (M) 187.5 (18.0) 81.0 (21.8)
 **
 0.46 
Tmax (min) 8.8 (1.3) 22.0 (9.4) 2.51 
AUC0-180 (M•min) 7659 (1127) 3444 (466)
 *
 0.45 
AUC0-∞ (M•min) 8883 (1400) 3696 (498)
 *
 0.42 
CL/F (ml/min) 0.486 (0.077) 1.152 (0.134)
 **
  2.37 
V/F (ml) 57.9 (9.3) 79.0 (16.5)
 
 1.36 
t1/2 (min) 83.3 (10.1) 48.3 (8.4)  0.58 
λZ (min
-1
) 0.0086 (0.0009) 0.0163 (0.0029) 1.89 
Data are expressed as mean (SE) (n=4-5).  
*
 p<0.05, 
**
 p<0.01, compared with 
wildtype mice. 
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Table 4.2 Compartmental analysis of 5-ALA after oral administration of 0.2 
mol/g [14C] 5-ALA in wildtype (WT) and PepT1 knockout (KO) mice 
 
Parameter (unit) Wildtype PepT1 KO Ratio (KO/WT) 
Cmax (M) 177 (11) 75 (21)
 **
 0.43 
Tmax (min) 9.2 (0.8) 21.8 (8.5) 2.37 
AUC0-∞ (M•min) 8788 (1210) 3850 (514)
 **
 0.44 
CL/F (ml/min) 0.485 (0.074) 1.109 (0.136)
 ** 
  2.29 
 t1/2 (min) 6.8 (1.1) 6.7 (1.8)  0.99 
 t1/2 (min) 98.5 (44.2) 54.9 (12.1)
 
  0.56 
Ka t1/2 (min) 5.1 (1.0) 13.9 (6.2) 2.73 
Ka (min
-1
) 0.159 (0.041) 0.140 (0.058) 0.88 
V1/F (ml) 11.1 (2.3) 36.8 (10.8)
 
 3.32 
V2/F (ml) 27.0 (12.6) 18.3 (7.4)
 
 0.68 
r
2
 0.984 (0.012) 0.951 (0.051) - 
Data are expressed as mean (SE) (n=4-5).  
*
 p<0.05, 
**
 p<0.01 compared with 
wildtype mice. 
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Table 4.3 Noncompartmental analysis of 5-ALA after oral administration of 2 
mol/g [14C] 5-ALA in wildtype (WT) and PepT1 knockout (KO) mice 
 
Parameter (unit) Wildtype PepT1 KO Ratio (KO/WT) 
Cmax (M) 1478 (97) 930 (88)
 **
 0.63 
Tmax (min) 10 (0) 10 (0) 1.00 
AUC0-180 (M•min) 68212 (6884) 31056 (6338)
 **
 0.46 
AUC0-∞ (M•min) 82207 (7925) 33807 (7689)
 **
 0.41 
CL/F (ml/min) 0.501 (0.052) 1.357 (0.262)
 *
  2.71 
V/F (ml) 79.8 (16.0) 107.5 (24.4) 1.35 
t1/2 (min) 108.8 (18.4) 56.8 (10.2)  0.52 
λZ (min
-1
) 0.0072 (0.0017) 0.0135 (0.0025) 1.87 
Data are expressed as mean (SE) (n=4).  
*
 p<0.05, 
**
 p<0.01, compared with 
wildtype mice. 
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Table 4.4 Compartmental analysis of 5-ALA after oral administration of 2 mol/g 
[
14
C] 5-ALA in wildtype (WT) and PepT1 knockout (KO) mice 
 
Parameter (unit) Wildtype PepT1 KO Ratio (KO/WT) 
Cmax (M) 1483 (61) 874 (90)
 **
 0.59 
Tmax (min) 11.4 (1.0) 8.1 (0.9) 071 
AUC0-∞ (M•min) 82511 (8116) 33961 (7504)
 **
 0.41 
CL/F (ml/min) 0.500 (0.053) 1.345 (0.259)
 ** 
  2.69 
 t1/2 (min) 8.2 (0.9) 6.1 (1.5)  0.74 
 t1/2 (min) 109.3 (14.2) 60.7 (5.2)
 *
  0.56 
Ka t1/2 (min) 6.9 (1.1) 5.4 (1.4) 0.78 
Ka (min
-1
) 0.109 (0.018) 0.150 (0.029) 1.38 
V1/F (ml) 11.6 (1.2) 20.0 (4.0)
 
 1.72 
V2/F (ml) 31.3 (4.5) 40.6 (8.3)
 
 1.30 
r
2
 0.989 (0.007) 0.963 (0.031) - 
Data are expressed as mean (SE) (n=4).  
*
 p<0.05, 
**
 p<0.01 compared with 
wildtype mice. 
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Table 4.5 Noncompartmental analysis of 5-ALA after intravenous bolus 
administration of 0.01 mol/g [14C] 5-ALA in wildtype (WT) and PepT1 
knockout (KO) mice  
Parameter (unit) Wildtype PepT1 KO Ratio (KO/WT) 
Vdss (ml) 6.68 (0.94) 7.62 (1.07)
 
 1.14 
AUC0-60 (M•min) 583 (61) 527 (71)
 
 0.90 
AUC0-∞ (M•min) 647 (65) 579 (71)
 
 0.89 
CL (ml/min) 0.338 (0.049) 0.377 (0.045)
 
  1.12 
t1/2 (min) 27.8 (2.0) 30.4 (4.6) 1.11 
MRTiv (min) 20.2 (2.4) 20.2 (2.4) 1.00 
Data are expressed as mean (SE) (n=7).  No statistical differences were observed 
between wildtype and PepT1 KO mice.  
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Table 4.6 Compartmental analysis of 5-ALA after intravenous bolus 
administration of 0.01 mol/g [14C] 5-ALA in wildtype (WT) and PepT1 
knockout (KO) mice 
Parameter (unit) Wildtype PepT1 KO Ratio (KO/WT) 
AUC0-∞ (M•min) 717 (94) 584 (75) 0.81 
CL (ml/min) 0.322 (0.058) 0.377 (0.047)
  
  1.17 
 t1/2 (min) 4.2 (0.6) 3.6 (0.4)   0.86 
 t1/2 (min) 65.0 (18.6) 36.5 (10.1)
 
  0.56 
K10 t1/2 (min) 6.9 (0.8) 5.8 (0.4) 0.84 
K10 (min
-1
) 0.109 (0.018) 0.150 (0.029) 1.38 
V1 (ml) 2.9 (0.4) 3.1 (0.4)
 
 1.07 
V2 (ml) 7.7 (1.6) 5.5 (1.2)
 
 0.71 
Vss (ml) 10.6 (1.5) 8.5 (1.3)
 
 0.80 
MRTiv (min) 40.5 (9.7) 23.8 (4.8) 0.59 
r
2
 0.963 (0.007) 0.962 (0.013) - 
Data are expressed as mean (SE) (n=7).  No statistical differences were observed 
between wildtype and PepT1 KO mice.  
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CHAPTER 5                                                                                             
FUTURE DIRECTION 
Peptide transporter PepT1 has been considered to play an important 
pharmacological role in transporting a wide spectrum of therapeutic compounds 
with di-/tri-peptide structure similarity. The prodrug strategy for targeting PepT1 
is under intense investigation to improve the oral absorption of certain drugs with 
relatively poor bioavailability. The role of PepT1 in facilitating 5-ALA intestinal 
absorption and improving oral bioavailability is worth characterizing, given the 
fact that 5-ALA is a polar and hydrophilic molecule and other intestinal 
transporters (e.g., PAT1) showed potential in mediating the active transport of 5-
ALA. In this dissertation, I have demonstrated the significant role of PepT1 in the 
intestinal permeability of 5-ALA via in situ single-pass perfusions and quantified 
the effect of PepT1 on intestinal absorption and systemic exposure of 5-ALA after 
clinically relevant oral doses. The relative contribution of intestinal transporter 
PepT1 in this process, as compared to other potential intestinal transporters such 
as PAT1, was also assessed and discussed in this dissertation. The clinical 
significance and importance of this project could be further elaborated and 
summarized in the following aspects. First, both PepT1 and PAT1 have been 
demonstrated to be pharmacologically important in the intestinal absorption of 
numerous therapeutic compounds and may share some common substrates (e.g. 5-
ALA in this case). The findings in this dissertation could provide useful 
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information in guiding future clinical studies on transporter related drug-drug 
interactions, which could affect the intestinal absorption of certain drugs (i.e., co-
administration of 5-ALA with other drugs which are also PepT1 or PAT1 
substrates). Second, results of PepT1-mediated uptake of 5-ALA create a better 
understanding of the structure-transport relationship of PepT1, which improve our 
understanding of drug ADME properties and eventually benefit drug development. 
Finally, pharmacogenetic studies of the human PEPT1 gene have shown genetic 
polymorphisms. Although current knowledge regarding the pharmaceutical and 
pharmacokinetic relevance of PEPT1 genetic variants is limited, we believe that 
genetic polymorphisms of PEPT1 may adversely influence the intestinal 
absorption of many drugs and this will become apparent with more research. 
Therefore, it is valuable to conduct the present study on 5-ALA oral absorption 
since our PepT1 knockout mice could be considered a unique animal model to 
mimic possible loss-of-function/activity genetic variants in human.  
As discussed in Chapters 3 and 4, direct evidence to rule out a potential 
role of PAT1 in the in vivo oral absorption of 5-ALA is still lacking. Our in situ 
experimental results suggested that PepT1 accounted for approximately 90% of 5-
ALA permeability in various small intestinal segments of wildtype mice while the 
potential contribution of other transporters (e.g., PAT1) was extremely low. 
However, as observed in our in vivo pharmacokinetic studies, the influence of 
PepT1 on the intestinal absorption and overall pharmacokinetic profiles of 5-ALA 
cannot be extrapolated from our permeability studies (i.e., approximate 2-fold 
change in systemic exposure versus 10-fold change in permeability). In this 
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regard, it would be worthwhile to directly investigate the potential contribution of 
PAT1 on the in vivo intestinal absorption and pharmacokinetics of 5-ALA in 
wildtype and PepT1 knockout mice after oral co-administration of 5-ALA and 
PAT1 inhibitors (e.g., 5-hydroxytryptophan). This could provide solid evidence 
whether or not PAT1 is involved in the oral absorption of 5-ALA in vivo and its 
relative contribution as compared to PepT1, if any. 
To better understand the mechanisms of 5-ALA intestinal absorption and 
further bridge the discrepancy between in situ and in vivo experimental results, 
future studies could be focused on developing an “advanced compartmental 
absorption and transit” (ACAT) model. In this context, GastroPlus® might be 
used to describe the pharmacokinetic profiles of 5-ALA after oral dosing and to 
delineate the contribution of PepT1 in the oral absorption process. Through this 
modeling and simulation approach, we should be able to fit and predict 5-ALA 
plasma concentration-time profiles in wildtype and PepT1 knockout mice after 
oral administration, to examine segmental contribution to the absorption of 5-
ALA, and to predict the relative contribution of PepT1-mediated active transport 
versus paracellular and transcellular passive diffusion of 5-ALA. In addition, this 
mechanism-based model could potentially be leveraged to predict the intestinal 
absorption and in vivo pharmacokinetics of 5-ALA in human by extrapolating 
from our animal data.   
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APPENDIX A                                                                                   
INDIVIDUAL DATA FROM CHAPTER 4 
Table A.1 Individual PK parameters of 5-ALA after 0.2 mol/g oral dose in 
wildtype (WT) and PepT1 knockout (P1) mice (two-compartmental model) 
ID 
Unit 
1 2 3 4 5 
Mean SE 
6 7 8 9 10 
Mean SE 
Geno WT WT WT WT WT P1 P1 P1 P1 P1 
Cmax M 186 168 151 139 202 169 12 32 20 99 101 124 75 21 
Tmax min 10.0 10.8 7.1 2.1 8.9 7.8 1.5 36.2 48.0 7.3 6.7 10.7 21.8 8.5 
AUC min*M 8935 11692 5768 6527 8756 8336 1041 3200 2630 4136 3633 5651 3850 514 
CL_F ml/min 0.448 0.342 0.693 0.613 0.457 0.511 0.063 1.250 1.521 0.967 1.101 0.708 1.109 0.136 
Alpha_HL min 6.53 5.28 9.92 18.14 5.44 9.06 2.42 3.61 2.92 13.29 6.72 7.03 6.72 1.83 
Beta_HL min 231.0 53.1 58.3 171.4 51.5 113.1 37.2 25.6 33.9 82.8 49.4 83.1 54.9 12.1 
K01_HL min 7.05 5.32 2.48 0.36 5.45 4.13 1.20 24.65 32.67 2.26 2.82 6.92 13.86 6.22 
K01 1/min 0.098 0.130 0.279 1.924 0.127 0.512 0.354 0.028 0.021 0.306 0.246 0.100 0.140 0.058 
Alpha 1/min 0.106 0.131 0.070 0.038 0.127 0.095 0.018 0.192 0.237 0.052 0.103 0.099 0.137 0.034 
Beta 1/min 0.0030 0.0130 0.0119 0.0040 0.0134 0.0091 0.0023 0.0271 0.0205 0.0084 0.0140 0.0083 0.0157 0.0036 
V1_F ml 7.8 11.2 17.5 26.8 8.0 14.2 3.6 46.0 74.1 28.8 22.6 12.4 36.8 10.8 
V2_F ml 64.6 11.5 17.7 50.1 14.3 31.6 10.8 0.1 0.2 30.8 29.5 30.7 18.3 7.4 
WT #4, an outlier, was removed from the final analysis in Tables 4.1 and 4.2. 
K01=Ka
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Table A.2 Individual PK parameters of 5-ALA after 0.2 mol/g oral dose in 
wildtype (WT) and PepT1 knockout (P1) mice (non-compartmental analysis) 
ID 
 
1 2 3 4 5 
Mean SE 
6 7 8 9 10 
Mean SE 
Geno Unit WT WT WT WT WT P1 P1 P1 P1 P1 
Cmax M 221 172 144 135 213 177 17 41.7 24.1 94.9 98.1 146 81 22 
Tmax min 10 10 5 5 10 8.0 1.2 45 45 5 5 10 22.0 9.4 
AUC 0-180 min*M 6587 10578 5343 4920 8128 7111 1031 2848 2233 3731 3405 5006 3444 466 
AUC 0-∞ min*M 7337 12245 5955 5301 9997 8167 1299 2974 2652 3799 3540 5517 3696 498 
CL/F ml/min 0.545 0.327 0.672 0.755 0.400 0.540 0.080 1.347 1.550 1.046 1.127 0.725 1.152 0.134 
V/F ml 60.2 31.5 74.9 65.8 65.0 59.5 7.4 66.5 120.2 56.9 74.3 74.3 79.0 16.5 
Lambda_z 1/min 0.0091 0.0104 0.0090 0.0115 0.0062 0.0092 0.0009 0.0194 0.0107 0.0254 0.0163 0.0098 0.0163 0.0029 
t1/2 min 76.6 66.8 77.3 60.4 112.6 78.7 9.0 35.7 64.8 27.3 42.5 71.1 48.3 8.4 
AUC 0-30 min*M 3946 3940 3006 2529 4211 3526 323 551 258 2062 1907 2714 1498 469 
AUC 0-45 min*M 4708 5418 3672 3147 5333 4455 452 1126 587 2561 2291 3394 1992 505 
AUC 0-60 min*M 5107 6546 4090 3549 6040 5066 565 1621 936 2852 2567 3827 2361 501 
AUC 0-90 min*M 5596 8249 4648 4130 6842 5893 748 2206 1496 3204 2922 4322 2830 477 
AUC 0-120 min*M 6009 9315 4954 4466 7363 6421 878 2555 1846 3457 3148 4625 3126 465 
AUC 0-150 min*M 6331 10013 5169 4724 7766 6801 960 2747 2070 3640 3306 4840 3321 464 
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Table A.3 Individual PK parameters of 5-ALA after 2 mol/g oral dose in 
wildtype (WT) and PepT1 knockout (P1) mice (two-compartmental model) 
ID 
 
1 2 3 4 
Mean SE 
5 6 7 8 
Mean SE 
Geno 
 
WT WT WT WT P1 P1 P1 P1 
Cmax M 1348 1455 1485 1643 1483 61 1054 678 768 995 874 90 
Tmax min 14.1 10.0 10.1 11.5 11.4 1.0 8.4 6.9 6.6 10.6 8.1 0.9 
AUC min*M 77105 62101 93030 97807 82511 8116 36482 23340 21827 54193 33961 7504 
CL_F ml/min 0.519 0.644 0.430 0.409 0.500 0.053 1.096 1.714 1.833 0.738 1.345 0.259 
Alpha_HL min 9.2 6.7 10.3 6.9 8.2 0.9 3.6 4.3 6.0 10.4 6.1 1.5 
Beta_HL min 128.8 107.3 131.3 70.0 109.3 14.2 62.5 57.6 48.9 73.8 60.7 5.2 
K01_HL min 9.58 6.68 4.36 6.92 6.88 1.07 9.37 4.44 3.18 4.51 5.38 1.37 
K01 1/min 0.072 0.104 0.159 0.100 0.109 0.018 0.074 0.156 0.218 0.154 0.150 0.029 
Alpha 1/min 0.076 0.104 0.068 0.100 0.087 0.009 0.195 0.161 0.116 0.066 0.135 0.028 
Beta 1/min 0.005 0.006 0.005 0.010 0.007 0.001 0.011 0.012 0.014 0.009 0.012 0.001 
V1_F ml 11.0 10.4 15.0 9.9 11.6 1.2 8.2 22.7 26.5 22.7 20.0 4.0 
V2_F ml 32.2 36.2 38.3 18.5 31.3 4.5 28.4 63.7 41.7 28.5 40.6 8.3 
K01=Ka 
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Table A.4 Individual PK parameters of 5-ALA after 2 mol/g oral dose in 
wildtype (WT) and PepT1 knockout (P1) mice (non-compartmental analysis) 
ID 
 
1 2 3 4 
Mean SE 
5 6 7 8 
Mean SE 
Geno Unit WT WT WT WT P1 P1 P1 P1 
Cmax M 1260 1380 1580 1690 1478 97 1180 810 805 924 930 88 
Tmax min 10 10 10 10 10 0 10 10 10 10 10 0 
AUC 0-180 min*M 64334 52949 69493 86073 68212 6884 34204 21741 20606 47676 31056 6338 
AUC 0-∞ min*M 75653 62845 95140 95189 82207 7925 35564 22828 21936 54900 33807 7689 
CL/F ml/min 0.529 0.636 0.420 0.420 0.501 0.052 1.125 1.752 1.823 0.729 1.357 0.262 
V/F ml 87.8 109.9 87.0 34.5 79.8 16.0 56.9 116.9 170.9 85.3 107.5 24.4 
Lambda_z 1/min 0.0060 0.0058 0.0048 0.0122 0.0072 0.0017 0.0198 0.0150 0.0107 0.0085 0.0135 0.0025 
t1/2 min 115.0 119.7 143.4 56.9 108.8 18.4 35.1 46.2 65.0 81.2 56.8 10.2 
AUC 0-30 min*M 31235 31140 32825 38275 33369 1680 21395 12275 13338 22630 17409 2678 
AUC 0-45 min*M 43138 38198 41810 49300 43111 2312 25903 14458 15820 29013 21298 3623 
AUC 0-60 min*M 49055 41565 47653 57303 48894 3240 28505 15951 17052 33415 23731 4298 
AUC 0-90 min*M 55745 45795 55333 68763 56409 4716 31010 18438 18435 39205 26772 5095 
AUC 0-120 min*M 59374 48752 60703 76383 61303 5694 32419 20109 19398 42850 28694 5586 
AUC 0-150 min*M 62077 51029 65383 81828 65079 6371 33371 21078 20100 45573 30030 5996 
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Table A.5 Individual PK parameters of 5-ALA after 0.01 mol/g intravenous dose 
in wildtype (WT) and PepT1 knockout (P1) mice (two-compartmental model) 
ID 
 
1 2 3 4 5 6 7 
Mean SE 
8 9 10 11 12 13 14 
Mean SE 
Geno Unit WT WT WT WT WT WT WT P1 P1 P1 P1 P1 P1 P1 
AUC min*M 515 1079 676 736 876 828 313 717 94 728 520 569 591 934 402 346 584 75 
CL ml/min 0.389 0.185 0.296 0.272 0.228 0.242 0.639 0.322 0.058 0.275 0.385 0.352 0.338 0.214 0.498 0.578 0.377 0.047 
Alpha_HL min 1.5 5.2 4.6 5.2 4.9 5.1 2.6 4.2 0.6 4.7 4.5 2.8 4.1 3.8 3.4 2.0 3.6 0.4 
Beta_HL min 19.6 110.8 34.5 52.6 147.7 73.0 16.9 65.0 18.6 94.3 30.1 36.3 33.9 16.6 27.6 17.0 36.5 10.1 
K10_HL min 4.3 8.8 7.7 9.4 7.4 6.6 4.2 6.9 0.8 7.1 6.6 4.4 6.2 5.7 4.9 5.5 5.8 0.4 
K10 1/min 0.162 0.079 0.090 0.074 0.094 0.105 0.166 0.110 0.015 0.098 0.106 0.159 0.111 0.123 0.143 0.125 0.123 0.008 
Alpha 1/min 0.455 0.133 0.152 0.133 0.142 0.135 0.268 0.202 0.046 0.147 0.154 0.244 0.170 0.182 0.206 0.353 0.208 0.027 
Beta 1/min 0.035 0.006 0.020 0.013 0.005 0.009 0.041 0.019 0.005 0.007 0.023 0.019 0.020 0.042 0.025 0.041 0.025 0.005 
V1 ml 2.4 2.4 3.3 3.7 2.4 2.3 3.8 2.9 0.3 2.8 3.6 2.2 3.0 1.7 3.5 4.6 3.1 0.4 
V2 ml 5.5 11.1 4.7 7.6 15.6 5.1 4.5 7.7 1.6 11.4 4.1 5.7 4.7 1.1 5.0 6.2 5.5 1.2 
Vss ml 7.9 13.4 8.0 11.3 18.0 7.4 8.3 10.6 1.5 14.2 7.7 7.9 7.7 2.8 8.5 10.8 8.5 1.3 
MRT min 20.4 72.4 27.0 41.5 78.7 30.6 13.0 40.5 9.7 51.8 20.1 22.4 22.8 13.3 17.1 18.6 23.7 4.8 
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Table A.6 Individual PK parameters of 5-ALA after 0.01 mol/g intravenous dose 
in wildtype (WT) and PepT1 knockout (P1) mice (non-compartmental analysis) 
ID 
 
1 2 3 4 5 6 7 
Mean SE 
8 9 10 11 12 13 14 
Mean SE 
Geno 
 
WT WT WT WT WT WT WT P1 P1 P1 P1 P1 P1 P1 
AUC 0-60 min*M 478 802 574 577 617 727 304 583 61 578 470 516 521 906 367 330 527 71 
AUC 0-∞ min*M 555 872 670 684 664 759 323 647 65 631 512 628 595 929 402 356 579 71 
Vdss ml 9.24 4.01 7.95 8.32 4.89 3.37 8.95 6.68 0.94 5.65 7.21 10.27 8.06 2.54 8.92 10.69 7.62 1.07 
CL ml/min 0.360 0.229 0.298 0.292 0.301 0.264 0.620 0.338 0.049 0.317 0.391 0.318 0.336 0.215 0.498 0.561 0.377 0.045 
t1/2 min 30.7 24.1 32.9 33.2 30.1 19.8 24.0 27.8 2.0 31.6 25.4 53.5 36.3 17.3 29.1 19.3 30.4 4.6 
Lambda_z 1/min 0.0226 0.0288 0.0211 0.0208 0.0230 0.0351 0.0289 0.0258 0.0020 0.0220 0.0273 0.0130 0.0191 0.0401 0.0238 0.0359 0.0259 0.0036 
MRT min 25.6 17.5 26.6 28.5 16.2 12.8 14.4 20.2 2.4 17.8 18.5 32.3 24.0 11.8 17.9 19.0 20.2 2.4 
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Diagnostic plots of two-compartmental model analysis 
Figure A.1 Individual predicted and observed plasma concentration-time profiles 
at 0.2 mol/g oral dose in wildtype (WT) mcie. 
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Figure A.2 Individual predicted and observed plasma concentration-time profiles 
at 0.2 mol/g oral dose in PepT1 knockout (P1) mcie. 
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Figure A.3 Individual predicted and observed plasma concentration-time profiles 
at 2 mol/g oral dose in wildtype (WT) mcie. 
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Figure A.4 Individual predicted and observed plasma concentration-time profiles 
at 2 mol/g oral dose in PepT1 knockout (P1) mcie. 
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Figure A.5 Individual predicted and observed plasma concentration-time profiles 
at 0.01 mol/g intravenous dose in wildtype (WT) mcie. 
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Figure A.6 Individual predicted and observed plasma concentration-time profiles 
at 0.01 mol/g intravenous dose in PepT1 knockout (P1) mcie. 
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APPENDIX B                                                                                 
POPULATION PHARMACOKINETIC MODELING OF CEFADROXIL 
RENAL TRANSPORT IN WILDTYPE AND PEPT2 KNOCKOUT MICE 
 
ABSTRACT 
Cefadroxil is a broad-spectrum -lactam antibiotic that is widely used in 
the treatment of various infectious diseases. Currently, poor understanding of the 
drug’s pharmacokinetic profiles and disposition mechanism(s) prevents 
determining optimal dosage regimens and achieving ideal antibacterial responses 
in patients. In the present study, we developed a population pharmacokinetic 
model of cefadroxil in wildtype and PepT2 knockout mice using the NONMEM 
approach. Cefadroxil pharmacokinetics were best described by a two-
compartment model, with both saturable and nonsaturable transport processes 
to/from the central compartment. Through this modeling approach, 
pharmacokinetic parameters in wildtype and PepT2 knockout mice were well 
estimated, respectively, as: volume of central compartment V1 (3.43 vs 4.23 ml), 
volume of peripheral compartment V2 (5.98 vs 8.61 ml), inter-compartment 
clearance Q (0.599 vs 0.586 ml/min), and linear elimination rate constant K10 
(0.111 vs 0.070 min
-1
).  Moreover, the secretion kinetics (i.e., Vm1 = 17.6 
nmol/min and Km1 = 37.1 M) and reabsorption kinetics (i.e., Vm2 = 15.0 
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nmol/min and Km2 = 27.1 M) of cefadroxil were quantified in kidney, for the 
first time, under in vivo conditions. Our model provides a unique tool to 
quantitatively predict the transporter-mediated nonlinear disposition of cefadroxil 
as well as optimize dose-response relationships. 
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INTRODUCTION 
Cefadroxil is a -lactam compound with a broad spectrum of antibacterial 
activity (Buck and Price 1977).  This semisynthetic and first-generation 
aminocephalosporin was shown more effective and resistant to -lactamases than 
cephalexin against certain bacteria (Ripa and Prenna 1979).  It has been 
commonly used in the treatment of different kinds of infections including skin, 
respiratory and urinary tract infections (Tanrisever and Santella 1986).  Due to its 
wide application for infectious diseases, a better understanding of cefadroxil 
pharmacokinetics would be of significant value for appropriate dose adjustment in 
patient subpopulations.  Clinical studies showed that, after oral administration, 
cefadroxil is rapidly and almost completely absorbed in the gastrointestinal tract 
(Tanrisever and Santella 1986; Barbhaiya 1996).  Cefadroxil is minimally 
metabolized, at best, in the body and excreted primarily by the kidney with over 
90% of the administered dose being recovered in the urine intact within 24 hours 
(Lode, Stahlmann et al. 1979; Nightingale 1980).  Experimental results have 
demonstrated that cefadroxil is a substrate of the peptide transporters PepT1 and 
PepT2, and several organic anion transporters (i.e., OATs) (Ganapathy, Brandsch 
et al. 1995; Shitara, Sato et al. 2005).  The renal elimination of cefadroxil is 
governed by glomerular filtration, OAT-mediated renal secretion, and PEPT2-
mediated renal reabsorption.  The collective contributions (or balance) between 
these processes determine the net renal clearance of cefadroxil.   
 PEPT2 (SLC15A2) belongs to the proton-coupled oligopeptide 
transporter (POT) family in which the primary function is to translocate various 
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di-/tri-peptides and peptidomimetics across biological membranes (Daniel and 
Kottra 2004; Smith, Clemencon et al. 2013).  To date, four members of the POT 
family have been identified in mammals (i.e., PEPT1, PEPT2, PHT1 and PHT2).  
Among the four transporter members, PEPT2 is recognized as a high-affinity, 
low-capacity transporter when compared to PEPT1.  PEPT2 is predominantly 
localized at the apical membrane of proximal tubule epithelial cells and is the 
major peptide transporter involved in the renal tubular reabsorption of many 
peptide-like drugs (e.g., bestatin, valacyclovir, 5-amino-levulinic acid) (Inui, 
Tomita et al. 1992; Ganapathy, Huang et al. 1998; Rodriguez, Batlle et al. 2006; 
Hu, Shen et al. 2007).  Previous findings by our laboratory (Shen, Ocheltree et al. 
2007) showed that deletion of the PepT2 gene in mice caused a dramatic increase 
in the in vivo renal and total clearances of cefadroxil, with concomitant decreases 
in systemic exposure.  Moreover, significant dose-dependent pharmacokinetics 
was observed in PepT2 knockout mice whereas a more modest dose-dependency 
was observed in wildtype mice.  In this analysis, the authors (Shen, Ocheltree et al. 
2007) proposed that wildtype mice were more influenced by capacity-limited 
tubular reabsorption and that PepT2 knockout mice were more influenced by 
capacity-limited secretion.  In reality, the analysis is more complex in which 
varying degrees of saturation occurred for each carrier-mediated process (i.e., 
Oat(s) for secretion and PepT2 for reabsorption), depending upon the plasma (and 
tubular) concentrations achieved relative to transport affinity.  Thus, a model that 
could accommodate the contributions of glomerular filtration and transporter-
mediated secretory/reabsorptive processes, along with their in vivo Km values, 
 139 
 
would provide a powerful tool in predicting cefadroxil drug levels over a wide 
dose range.   
Characterization of transporter-mediated nonlinear pharmacokinetics is of 
importance in understanding and predicting pharmacologic actions of drugs, and 
sometimes difficult to achieve via traditional pharmacokinetic analyses.  Thus, a 
nonlinear mixed effect modeling (NONMEM) approach can be utilized to address 
different sources of variability and allow the estimation of all the kinetic 
parameters of interest (i.e., nonlinear and/or linear pharmacokinetic parameters) 
(Beal and Sheiner 1984).  This method has been employed to analyze transporter-
mediated nonlinear pharmacokinetics of several compounds including cefuroxime, 
glycylsarcosine and levofloxacin (Ruiz-Carretero, Merino-Sanjuan et al. 2004; 
Huh, Hynes et al. 2013; Hurtado, Weber et al. 2014).  Hence, the purpose of this 
study was to develop a population pharmacokinetic model of cefadroxil in 
wildtype and PepT2 knockout mice using the NONMEM approach.  With this 
pharmacokinetic model, we were able to describe the nonlinear pharmacokinetics 
of cefadroxil with emphasis on quantifying the importance and contribution of 
transporters during in vivo saturable renal tubular secretion and reabsorption 
processes. 
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MATERIALS AND METHODS 
Animals   
All animal studies were performed in accordance with the Guide for the 
Care and Use of laboratory Animals as adopted and promulgated by the U.S. 
National Institutes of Health.   
Experimental Design   
The pharmacokinetic profiles of cefadroxil were assessed in wildtype and 
PepT2 knockout mice using NONMEM, based on data generated previously by 
our laboratory (Shen, Ocheltree et al. 2007).  In brief, gender-matched mice (6-8 
weeks) were fasted overnight before the onset of each experiment.  After 
anesthesia with sodium pentobarbital, mice were administered [
3
H]cefadroxil (5 
L/g and 0.5 Ci/g body weight) intravenously by tail vein injection.  Blood 
samples (approximately 15 μL) were collected into heparinized tubes via tail 
nicks at pre-determined times (i.e., 0.25, 1, 2, 5, 15, 30, 45, 60, 90 and 120 min) 
after drug administration.  Plasma samples were harvested immediately after 
centrifuging the blood at 2000 g for 10 min.  The radioactivity of plasma samples 
was measured by a dual-channel liquid scintillation counter (Beckman LS 3801; 
Beckman Coulter, Inc., Fullerton, CA).  To investigate the dose dependency of 
cefadroxil pharmacokinetics, ascending doses of [
3
H]cefadroxil were 
administered separately to both genotypes (1, 12.5, 50 and 100 nmol/g body 
weight).   
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Noncompartmental Analysis of Cefadroxil Pharmacokinetics 
  Noncompartmental analysis (NCA) of the individual profiles was 
performed using Phoenix WinNonlin version 1.3 (Pharsight Corp., St. Louis, MO).  
Pharmacokinetic parameters, such as total clearance (CL), volume of distribution 
steady-state (Vdss), terminal half-life (T1/2), mean residence time (MRT), and area 
under the plasma concentration-time curve (AUC), were calculated using standard 
methods.   
Population Pharmacokinetic Modeling of Cefadroxil   
Population pharmacokinetic analyses were conducted using NONMEM 
software (Version 7.2, Icon Development Solutions, MD, USA).  The first-order 
conditional estimates (FOCE) method, with an interaction option implemented in 
NONMEM, was used for estimation.  All models were parameterized as a system 
of differential equations using the ADVAN 6 TRANS 1 subroutine in NONMEM.  
Model diagnostic plots were performed using R software (version 2.15.0) with the 
Xpose package. 
For the modeling development strategy, a sequential compartmental model 
building approach was adopted.  Different compartmental models, including one-, 
two- and three-compartments, were tested on the cefadroxil pharmacokinetic 
profiles after intravenous administration.  The analyses revealed that a two-
compartment model best described the structural model of cefadroxil.  After that, 
different population pharmacokinetic models, with linear elimination and/or 
nonlinear Michaelis-Menten kinetics for renal tubular secretion from the central 
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compartment, were tested in PepT2 knockout mice.  The final pharmacokinetic 
model  (Fig. 5.1A) was described by the following equations:    
 
 dA(1)/dt = -Vm1*C/(Km1+C) - K10*A(1) - K12*A(1) + K21*A(2)      (1) 
 dA(2)/dt = K12*A(1) - K21*A(2)  (2) 
 
where A(1) is the amount of cefadroxil in central compartment, A(2) is the 
amount of cefadroxil in peripheral compartment, C is the concentration of 
cefadroxil in central compartment, Vm1 is the maximum rate of saturable renal 
elimination from central compartment, Km1 is the Michaelis-Menten constant for 
saturable renal elimination from central compartment, K12 and K21 are the inter-
compartment rate constants describing cefadroxil transport between the two 
compartments, and K10 is the linear elimination rate constant from central 
compartment.   
Once the pharmacokinetic model for PepT2 knockout mice was 
established, the model was extended to include nonlinear Michaelis-Menten 
kinetics for the renal tubular reabsorption of cefadroxil in wildtype mice.  The 
final pharmacokinetic model for wildtype mice (Fig. 5.1B) was described by the 
following equations: 
 
dA(1)/dt = -Vm1*C/(Km1+C) + Vm2*C/(Km2+C) - K10*A(1) - K12*A(1) + K21*A(2)  
 (3) 
dA(2)/dt = K12*A(1) - K21*A(2)                                                                           (4)           
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where Vm2 is the maximum rate of saturable renal reabsorption and Km2 is the 
Michaelis-Menten constant for saturable renal reabsorption.  Inter-individual 
variability (IIV or ) for the pharmacokinetic parameters was described by an 
exponential model as shown below:  
 
  i = ×exp (i)                         (5) 
 
where i is the pharmacokinetic parameter of the i
th
 individual, is the population 
parameter estimate, and i is the IIV which is assumed to follow a normal 
distribution with mean of zero and variance of 2.  The residual variability was 
tested by different error models and best described by exponential error model.  
Model selection was based upon visual inspection of diagnostic goodness-
of-fit plots, precision of parameter estimates, and numerical comparison of the 
objective function value by decreasing at least 6.63 (log-likelihood ratio test; p < 
0.01).   
Nonparametric Bootstrap Analysis   
To check stability of the final population pharmacokinetic model and 
obtain confidence intervals (CI) for the model parameters, nonparametric 
bootstrap analyses (n=1,000) were performed using Perl-speaks-NONMEM (PsN) 
3.6.2 (http://psn.sourceforge.net) (Lindbom, Ribbing et al. 2004; Keizer, Karlsson 
et al. 2013).  Specifically, 1,000 replicate bootstrap data sets using subjects as 
sampling units were generated by random resampling with replacement from the 
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original data set.  Stratification by dose during the random resampling process 
was implemented to ensure that the bootstrap data sets adequately represented the 
original data.  Each new sample set was fitted to the final population 
pharmacokinetic model to obtain parameter estimates.  The empirical 90% CI 
were constructed by obtaining the 5
th
 and 95
th
 percentiles of parameter 
distributions from the successful bootstrap runs.  Final model parameter estimates 
were compared with bootstrap median parameter estimates to evaluate the final 
model performance. 
 
Visual Predictive Check   
To assess predictive performance of the final population pharmacokinetic 
model, a prediction-corrected visual predictive check (pcVPC) (Bergstrand, 
Hooker et al. 2011) with 1,000 data sets simulation was performed.  The median, 
5
th
 and 95
th
 percentiles of the simulated concentrations were calculated at each 
time point, and checked by visual inspection to see how the simulated intervals 
overlapped with the observed data.  
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RESULTS 
Noncompartmental Analysis of Cefadroxil Pharmacokinetics    
To examine the influence of PepT2 and/or Oat(s) in affecting the 
disposition of cefadroxil, and potential for saturation, a pharmacokinetic study 
was performed in wildtype and PepT2 knockout mice after intravenous dosing of 
drug over a 100-fold dose range (Figure B.2). Cefadroxil pharmacokinetic 
parameters were estimated by a non-compartmental analysis as summarized in 
Table B.1.  When the highest dose (100 nmol/g) was administered, only minor 
differences were observed between genotypes in the pharmacokinetics of drug 
(e.g., < 15% higher total clearance during PepT2 ablation).  However, when the 
lowest dose (1 nmol/g) was administered, the pharmacokinetics of cefadroxil was 
substantially different between wildtype mice and PepT2 knockout animals (e.g., 
3-fold higher total clearance during PepT2 ablation). These findings suggest that 
the pharmacokinetics of cefadroxil is nonlinear, primarily reflecting the 
saturability of PepT2-mediated tubular reabsorption in kidney at the higher dose 
comparison.  Moreover, as the doses increase, the total clearance of cefadroxil in 
PepT2 knockout mice is steadily reduced, thereby, suggesting saturability of 
Oat(s)-mediated renal secretion of drug at the higher dose levels. 
   
Population Pharmacokinetic Modeling   
To sequentially build a population pharmacokinetic model for cefadroxil 
in mice, the plasma concentration versus time profiles of drug over the dose range 
studied were first fitted by NONMEM in PepT2 knockout mice.  A two-
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compartment model, comprised of both saturable and nonsaturable efflux 
processes from the central compartment, was selected as the final model.  The 
system of differential equations for the final model was given in Equations 1 and 
2.  Estimated pharmacokinetic parameters of cefadroxil in the final model of 
PepT2 knockout mice are listed in Table B.2.  In this model, the nonlinear 
kinetics of renal tubular secretion are well characterized by the Michaelis-Menten 
parameters Vm1 and Km1 which reflect the Oat(s)-mediated vectorial secretion of 
cefadroxil across renal epithelial cells.   
The population pharmacokinetic model for wildtype mice was developed 
subsequently by adding a saturable component, for the cellular influx of 
cefadroxil from tubular fluid into the central compartment, to describe the 
transporter-mediated uptake of drug in wildtype mice.  The system of differential 
equations for this final model was shown as Equations 3 and 4.  The 
pharmacokinetic parameter estimates of cefadroxil in this final model are shown 
in Table B.2 for wildtype mice.  It should be noted that the values of Vm1 and Km1, 
as determined previously in PepT2 knockout mice, were fixed in this 
pharmacokinetic model of wildtype mice.  All parameters were estimated with 
high precision.  In particular, the Michaelis-Menten kinetics were well 
characterized, as judged by the low values of RSE (< 25%) for Vm2 and Km2, 
which reflect the PepT2-mediated vectorial reabsorption of cefadroxil across renal 
epithelial cells.   
Final Model Validation   
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Basic goodness-of-fit plots of the final pharmacokinetic models were 
displayed in Figure B.3 and B.4.  As observed, the individual and population 
predictions were in good agreement with observed plasma concentrations in both 
wildtype and PepT2 knockout mice.  Moreover, the conditional weighted 
residuals (CWRES) do not deviate from zero (i.e., no significant trend) with 
respect to time or individual prediction.  Overall, the results suggest there is no 
misspecification of the final pharmacokinetic models in both genotypes.   
The final models were further evaluated using a nonparametric bootstrap 
analysis.  The empirical 90% CI was constructed by obtaining the 5
th
 and 95
th
 
percentiles of the parameter distributions from the successful bootstrap runs.  As 
shown in Table B.3, pharmacokinetic parameter estimates from the original data 
were very similar to median values obtained from the bootstrap estimates, and 
were within the bootstrap confidence intervals indicating there was no significant 
bias in the final model parameters.   
To assess predictive performance of the final pharmacokinetic model, a 
prediction-corrected visual predictive check of cefadroxil plasma concentration-
time profiles was performed using 1,000 data set simulations (Fig. B.5).  The 
median, 5
th
 and 95
th
 percentiles of simulated concentrations were calculated at 
each time point and then checked by visual inspection to compare how the 
simulated results overlap with the observed data.  As shown, approximately 90% 
of observed data fall into the region covered by 5
th
 and 95
th
 percentiles of 
simulated data, thus, indicating that the final models adequately predict the 
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observed plasma concentrations of cefadroxil with respect to the average (median) 
and the spread of the data (prediction interval).    
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DISCUSSION 
The pharmacodynamic response to an antibacterial agent is largely 
determined by the antibacterial activity of the drug, which depends on its 
exposure at pharmacological target sites and pharmacokinetic profiles.  Therefore, 
in-depth understanding of the pharmacokinetic profiles and its disposition 
mechanism(s) is crucial to determine optimal dosage regimens for achieving ideal 
antibacterial effects in patients.  It is of interest that several contradictory studies 
on cefadroxil pharmacokinetics have been reported in humans and animals 
(Marino and Dominguez-Gil 1980; La Rosa, Ripa et al. 1982; Santella and 
Henness 1982; Garrigues, Martin et al. 1991; Garcia-Carbonell, Granero et al. 
1993; Posada and Smith 2013).  Some studies described a dose-linearity in 
pharmacokinetics, whereas others found dose-dependent changes in 
pharmacokinetic profiles. Regardless, the molecular mechanisms that affect the 
pharmacokinetics and tissue distribution of cefadroxil was lacking until our recent 
studies in genetically modified mice (Shen, Smith et al. 2003; Shen, Ocheltree et 
al. 2007; Kamal, Keep et al. 2008).  Due to the availability of PepT2 knockout 
mice, we were able to elucidate the role and relevance of this oligopeptide 
transporter in the renal and systemic disposition of cefadroxil in wildtype mice 
and during PepT2 ablation (Shen, Ocheltree et al. 2007).  Our experimental data 
clearly demonstrated that PepT2, as opposed to PepT1, had a predominant role in 
the renal tubular reabsorption of cefadroxil, accounting for 95% of the drug’s 
reabsorption in kidney.  However, because the transport kinetics (i.e., Vm and Km) 
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of cefadroxil were not characterized, for either secretory or reabsorptive transport, 
predictability of dose-response relationships was not possible.   
In the present report, several new findings were revealed.  In particular, 
this was the first study to examine a semi-mechanistic population 
pharmacokinetic model of cefadroxil transport in kidney.  Moreover, we 
quantified the secretion kinetics (i.e., Vm1 = 17.6 nmol/min and Km1 = 37.1 M) 
and reabsorption kinetics (i.e., Vm2 = 15.0 nmol/min and Km2 = 27.1 M) of 
cefadroxil in kidney under in vivo conditions.  In doing so, the potential for 
capacity-limited transport of cefadroxil can be better predicted and, thus, result in 
an optimized host response to invading bacteria.  For example, plasma 
concentrations produced at the 1 nmol/g intravenous dose of cefadroxil were 
approximately 0.01-10 M, values that fall into the range of minimal inhibitory 
concentrations for most, but not all, bacteria (Hartstein, Patrick et al. 1977; 
Courtieu and Drugeon 1983).  By defining the entire pharmacokinetic profile of 
cefadroxil, relevant concentrations in plasma (and urine) can now be determined 
across a wide range of doses, a priori, and compared to bacterial susceptibility for 
a more favorable drug response.   
The renal clearance of cefadroxil is governed by three processes, which 
are glomerular filtration, renal tubular secretion, and renal tubular reabsorption.  
Since renal clearance, glomerular filtration and fraction unbound in plasma can be 
determined, and given the (almost) exclusive reabsorption of drug by PepT2 in 
kidney (Shen, Ocheltree et al. 2007), it was possible to estimate the Oat(s)-
mediated nonlinear and linear contributions (i.e., 62% and 38%, respectively) to 
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cefadroxil renal excretion in PepT2 knockout mice.  In the present study, we 
found the Km1 for Oat(s) vectorial secretion to equal 37.1 M, a value much lower 
than the millimolar values of IC50 and/or Ki reported previously for cefadroxil in 
renal proximal tubule cells expressing rat Oat1-3 (Jung, Takeda et al. 2002; 
Khamdang, Takeda et al. 2003) and human OAT1-4 (Takeda, Babu et al. 2002; 
Khamdang, Takeda et al. 2003).  Although speculative, this disparity may result 
from the different species and experimental systems being employed.  Moreover, 
IC50 and Ki values obtained from the in vitro inhibition of a model substrate by 
cefadroxil do not necessarily represent the Km values of cefadroxil obtained 
under in vivo physiological conditions.  On the other hand, the Km2 value of 27.1 
M for vectorial reabsorption of cefadroxil is in good agreement with other 
investigators, who reported Km values for cefadroxil of 9 M in rat kidney brush 
border membrane vesicles (Ries, Wenzel et al. 1994), 17 M (Shen, Keep et al. 
2005) and 27 M (Ocheltree, Shen et al. 2004) in rat isolated choroid plexus, 39 
M in rat choroid plexus primary cell cultures (Shen, Keep et al. 2005) and 32 
M in rabbit PepT2-expressing Xenopus oocytes (Boll, Herget et al. 1996).  It 
should be appreciated that cefadroxil is reabsorbed from luminal fluid by PepT2 
localized on the apical membrane of renal proximal tubule cells.  Therefore, the 
estimated Km2 is an apparent value in which plasma concentrations were used as 
surrogate values for drug concentrations in luminal fluid at the transport 
membrane site in order to fit the model.  Notwithstanding this uncertainty, these 
two biological fluids are likely close in value since cefadroxil is 80% unbound in 
plasma (Shen, Ocheltree et al. 2007).  
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Many studies have shown transporters to be major determinants of the 
pharmacokinetic, safety and efficacy profiles of drugs.  Moreover, single 
nucleotide polymorphisms of drug transporters, identified by advanced 
sequencing technology, appear to be responsible for the variation in drug 
responses among individuals (Evans and Relling 1999; Evans and McLeod 2003).  
In this regard, the proton-coupled oligopeptide transporter PepT2 had significant 
effects on peptide-like drug disposition as well as drug action and toxicity (Hu, 
Shen et al. 2007; Kamal, Keep et al. 2008).  Genetic variants of the PEPT2 gene 
have been reported in humans with functional polymorphisms (Pinsonneault, 
Nielsen et al. 2004; Terada, Irie et al. 2004; Liu, Tang et al. 2011).  For example, 
Terada et al. (43) found that the genetic variant R57H of PEPT2 completely lost 
its transport activity of glycylsarcosine, a substrate of PepT2, in transfected 
HEK293 cells and Xenopus oocytes.  Based on our results, we confirmed that 
PepT2 played an overwhelmingly predominant role in the tubular reabsorption of 
cefadroxil, an aminocephalosporin peptide-like drug.  Thus, it is conceivable that 
patients with PEPT2 deficiency may experience a substantial reduction in the 
reabsorption of certain drugs in kidney, thus, influencing efficacy due to 
decreased renal and systemic exposure.  The semi-mechanistic population 
pharmacokinetic model presented in this study provides a unique tool to 
quantitatively predict the transporter-mediated nonlinear disposition of cefadroxil.  
Further studies will be focused on extrapolating this model to humans once more 
information is gathered regarding relevant transporter expression profiles and 
other interspecies differences.  In doing so, a physiologically based 
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pharmacokinetic model may provide mechanistic insight and better predictability 
of cefadroxil pharmacokinetics, as well as dosage optimization and response in 
patient subpopulations.   
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FIGURES 
 
 
Figure B.1 Schematic two-compartment models of cefadroxil after intravenous 
bolus administration in PepT2 knockout (A) and wildtype (B) mice.   
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Figure B.2 Plasma concentration-time profiles of cefadroxil after intravenous 
bolus administrations of 1, 12.5, 50 and 100 nmol/g in PepT2 knockout (A) and 
wildtype (B) mice.  The figures were adapted from a previous publication (Shen, 
Ocheltree et al. 2007).  
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Figure B.3 Goodness-of-fit plots for the final pharmacokinetic model of 
cefadroxil in PepT2 knockout mice. Solid lines represent the line of identity.   
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Figure B.4 Goodness-of-fit plots for the final pharmacokinetic model of 
cefadroxil in wildtype mice. Solid lines represent the line of identity.   
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(A) PepT2 Knockout 
 
(B) Wildtype 
 
 
 
Figure B.5 Prediction corrected visual predictive check plots in PepT2 knockout 
(A) and wildtype (B) mice. Plasma concentration-time profiles are displayed in 
which the circles represent prediction corrected observed data. Dashed lines 
depict the 5
th
 and 95
th
 percentiles, and solid lines represent the median values of 
1,000 simulated data sets. 
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Table B.1 Noncompartmental analysis of cefadroxil pharmacokinetics in PepT2 
knockout (KO) and wildtype mice after intravenous bolus administration
a 
Genotype Parameters (units) 
Dose (nmol/g) 
1 12.5 50 100 
 
PepT2 KO 
 
Vdss (ml) 
 
20.9 ± 2.9 
 
10.5 ± 2.4
b
 
 
9.4 ± 2.8
b
 
 
7.9 ± 2.7
b
 
 T1/2 (min) 20.9 ± 2.2 22.2 ± 1.7 19.2 ± 2.8 21.9 ± 3.1 
 CL (ml/min) 1.03 ± 0.13 0.60 ± 0.20 0.50 ± 0.12
b
 0.40 ± 0.11
b
 
 MRT (min) 17.7 ± 1.3 17.1 ± 1.4 16.8 ± 2.6 16.9 ± 1.0 
 AUC0-tlast (M·min) 22 ± 4 521 ± 117
b
 2372 ± 542
b
 5924 ± 1304
b
 
 
 
Wildtype 
 
Vdss (ml) 
 
10.3 ± 1.3 
 
10.9 ± 4.5 
 
8.1 ± 1.1 
 
8.3 ± 1.4 
 T1/2 (min) 32.0 ± 3.0 28.3 ± 5.0 17.9 ± 0.8
b
 24.0 ± 2.8 
 CL (ml/min) 0.330 ± 0.041 0.322 ± 0.061 0.360 ± 0.033 0.352 ± 0.027 
 MRT (min) 24.5 ± 0.7 24.0 ± 2.8 20.4 ± 1.6 20.5 ± 2.5 
 AUC0-tlast (M·min) 67 ± 13 828 ± 155
b
 2825 ± 314
b
 5658 ± 424
b
 
      
 
a 
Data are expressed as mean ± SE (n=4-7). 
b 
p < 0.05 compared to 1 nmol/g dose of cefadroxil, as determined by ANOVA 
followed by Dunnett’s test. 
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Table B.2 Parameter estimates of the final population pharmacokinetic model of 
cefadroxil in PepT2 knockout (KO) and wildtype mice after intravenous bolus 
administration 
PepT2 KO Estimate   RSE (%) 
Primary parameters (units)    
   Vm1 (nmol/min) 17.6 17.2 
   Km1 (M) 37.1 35.8 
   V1 (ml) 4.23 12.2 
   Q (ml/min)
a
 0.586 20.5 
   V2 (ml) 8.61 16.7  
   K10 (min
-1
) 0.070 28.1 
Intersubject variabiliby (% CV)   
   Vm1 24.7 26.8 
   V1 42.7 15.1 
Residual variabiliby (% CV)   
   Proportional error 41.1 8.3 
Wildtype Estimate   RSE (%) 
Primary parameters (units)
b
   
   Vm2 (nmol/min) 15.0 23.5 
   Km2 (M) 27.1 24.0 
   V1 (ml) 3.43 7.2 
   Q (ml/min)
a
 0.599 21.2 
   V2 (ml) 5.98 14.4  
   K10 (min
-1
) 0.111 13.0 
Intersubject variabiliby
 
(%  CV)   
   V1 23.6 23.5 
   V2 42.5 26.5 
Residual variabiliby (% CV)   
   Proportional error 26.4 8.7 
 
a
 Q = V1K12 = V2K21 
b
 In determining the estimates in wildtype mice, Vm1 = 17.6 nmol/min and Km1 = 
37.1 M, as determined previously in PepT2 knockout mice.   
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Table B.3 Comparison of parameter estimates of the final population 
pharmacokinetic model of cefadroxil in PepT2 knockout (KO) and wildtype mice 
based on the original data set and from 1,000 bootstrap replicates 
 
  
Parameters Estimate 
Nonparametric Bootstrap 
Median 
90% Confidence 
Interval 
PepT2 KO 
   Vm1 (nmol/min) 
 
17.6 
 
17.5 
 
 
8.1 – 49.0 
   Km1 (M) 37.1 40.7 21.2 - 76.2 
   V1 (ml) 4.23 4.27 3.57 - 4.90 
   Q (ml/min) 0.586 0.589 0.394 - 0.757 
   V2 (ml) 8.61 8.52 6.98 - 10.70 
   K10 (min
-1
) 0.070 0.073 0.063 - 0.100 
Wildtype 
   Vm2 (nmol/min) 
 
15.0 
 
15.3 
 
 
8.6 - 28.3 
   Km2 (M) 27.1 28.0 16.8 - 46.9 
   V1 (ml) 3.43 3.44 3.05 - 3.82 
   Q (ml/min) 0.599 0.608 0.429 - 0.807 
   V2 (ml) 5.98 5.89 4.65 - 7.58 
   K10 (min
-1
) 0.111 0.110 0.089 - 0.163 
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